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ABSTRACT 
 
The proliferating phenotype is highly glycolytic and reliant on sufficient supply and synthesis of 
biosynthetic intermediaries to meet the demands of rapid cell replication.  Glutamine 
contributes to this up-regulated synthetic machinery by providing critical anaplerotic carbon to 
the TCA cycle; nitrogen for nucleoside production; and, through its rapid conversion to lactate, 
the reducing agent NADPH necessary to maintain the increase in anabolic activity.  Glutaminase 
represents a key step in this catabolism of glutamine and has been shown to be up-regulated in 
many different proliferating tissues.  It presents a target for the possible suppression of 
undesired proliferation in over-reactive immunity. 
The expression of the three Glutaminase isoforms (KGA, LGA & GAC) where partially 
characterized using Western Blots in mature naïve and proliferating human CD4+ T 
lymphocytes after TCR-CD3/CD28 activation.  Two Glutaminase inhibitors, BPTES and 
compound 968, were evaluated through 3H-Thymidine incorporation assays and mass 
spectrometry analysis of glutamine flux.  In addition, the effects of glutamine removal from 
proliferating populations of human CD4+ T lymphocytes were also analysed 
Our results showed glutamine is absolutely necessary for optimal CD4+ T lymphocyte 
proliferation and that the Glutaminase isoform GAC is up-regulated in proliferating human CD4+ 
T lymphocytes. Its inhibition leads to attenuation in proliferative activity.   
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1.0 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
 
The mammalian immune system encompasses the cells, tissues and molecules that endow the 
host organism with the ability to protect itself from infection and disease1. An immune response 
is the coordinated reaction of this system against an infection.  Deficiencies in the immune 
system can quickly lead to serious illness and even death - illustrating the importance of 
immunity to the survival of the organism. 
 
Host organisms have two main tiers of defence against foreign infections: innate and adaptive 
immunity2.  Innate immunity describes the initial defence an organism mounts against infection.  
A healthy organism develops with this system fully functional.  Adaptive immunity matures over 
time and mediates a more effective response to any subsequent infection. There are two types 
of adaptive immunity: humoral and cell-mediated immunity.  Each consists of a separate set of 
cells and molecules that protect against extracellular and intracellular microbes, respectively.  
1.1.1  CELLS OF AN IMMUNE RESPONSE 
 
Skin, mucus in the natural openings of the body, epithelial barriers, and the specialised cells that 
reside in these barriers provide a first line of defence against the entry of microbes in the innate 
immune system1. The specialized cells include phagocytes (also called macrophages) which 
engulf and breakdown antigens. Antigens are substances produced by microbes, and, in 
addition, include virus, bacteria, fungus, parasites, carcinogens, pollution, and a vast number of 
toxins. When an antigen enters the body it normally elicits an infection.   The classical signs of an 
infection are often acute inflammation characterized by activation of a number of immune cells, 
including macrophages and dendritic cells (DC).  Activation of these cells stimulates release of 
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inflammatory mediators that account for the clinical signs of infection.   These inflammatory 
mediators increase blood perfusion to the infected area (inflammation) that allow for the rapid 
recruitment of a group of specialised cells, collectively called leukocytes.    
Extravasation describes the movement of the various leukocytes critical to the initiation and 
eradication of an infection and involve chemokine and receptor-mediated migration and 
adhesion2. The products of the cells involved in the infection also promote cell surface receptor 
expression on immune cells in the blood stream enabling them to roll slowly along the 
endothelial surface in order to migrate and stop at the infection site.  The complement, 
coagulation, and fibrinolysis cascade systems also act in unison to initiate, propagate and 
maintain this inflammatory response. 
1.1.1.1 Leukocytes 
 
Leukocytes are a diverse group of specialised immune cells that protect the body against 
infection and foreign matter1.  There are five in total, distinct in function and often characterised 
as granulocytes or mononuclear cells.  Granules of membrane-bound enzymes in the cytoplasm 
that digest endocytosed particles characterise granulocytes, also called polymorphonuclear 
leukocytes3.   There are three types of granulocytes: neutrophils, basophils, and eosinophils.  
Mononuclear leukocytes are characterised by the absence of granules in their cytoplasm.  There 
are three types: monocytes, macrophages and lymphocytes (see Fig 1). 
 
  INTRODUCTION 
9 
 
 
Figure 1. Differentiation of human leukocytes. A hematopoietic stem cell can differentiate into two 
lineages: (to the left)into  stem cells  that differentiate into precursors that eventually become either red 
blood cells, platelets, the two mononuclear cells, Monocytes and Macrophages, or the granulocytes 
(Eosinophils, Basophils and Neutrophils); or (to the right) into lymphoid stem cells that differentiate into 
either Natural Killer (NK) cells or lymphoblasts that become either T or B lymphocytes3.  
 
1.1.1.2 Lymphocytes 
 
There are three classes of mammalian lymphocytes: T-cells, B-cells and Natural Killer cells (NK 
cells). The populations of these lymphocytes are kept relatively stable throughout an organism’s 
lifespan4. This homeostasis is achieved through a tightly regulated system of targeted apoptosis 
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and autophagy involving antigens, cytokines (small, hormone-like extracellular messenger 
molecules) and other co-stimulatory signals.  Naive lymphocytes can live a surprisingly long life 
and spend most of their existence circulating through the lymphatic system.   T cell lineage is 
differentiated by the type of protein expressed on the surface of the cell3.  “CD” denotes “Cluster 
of Differentiation” and is the standard nomenclature used to differentiate T cell phenotypes. 
 
Natural Killer cells (NK cells) are a part of the adaptive immune response1.  They are a type of 
cytotoxic lymphocyte that provides rapid response to virally infected cells and tumour 
formation.  They are active around three days after infection.  
B cells have three main tasks: generate antibodies against antigens, function as antigen-
presenting cells (APC; see below), and develop into memory B cells after activation.  The B cell is 
a key component in humoral immunity (“humours” = extracellular fluids of the body), which 
includes secreted antibodies, complement proteins and certain antimicrobial peptides.  B cells 
can be distinguished from other lymphocytes by several cell surface markers. One such marker, 
the protein complex known as a B cell receptor (BCR), allows the B cell to bind to specific 
antigens.   
T cells also express antigen receptors on their surface. This receptor is called a T cell antigen 
receptor (TCR).  That BCRs and TCRs are formed randomly in order to recognize any antigen 
make B and T cells key mediators of adaptive immunity.  
1.1.2  T CELLS 
1.1.2.1 T cell subtypes 
 
There are five main T-cell subtypes, all expressing either the CD4 or the CD8 surface marker5. 
The CD4 and CD8 molecules serve to stabilize the interaction between the TCR complex and the 
Major Histocompatibility Complex (MHC II and I) protein molecules, expressed on various other 
cells, including APCs. The subgroups of T cells include: “Regulatory” T cells (Tregs)which  
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suppress immunity; whereas “Natural Killer” T cells (not to be confused with NK cells) act in a 
similar way to cytotoxic T cells but are part of the innate response and do not adapt in response 
to an antigen or infection.  The largest groups of T cells are made up of the “Helper” T-cells or 
CD4+ T cells, and the “Cytotoxic” T-cells  or  CD8+ T cells which are the basis for the development 
of “Memory” T cells.  Memory T cells are hallmarks of a highly developed organism and will 
expand more rapidly into helper or cytotoxic T-cells in response to re-infection.  CD8+ T cells 
(cytotoxic T cells, TC cells, or CTLs) recognise their targets by binding to antigens associated 
with MHC I – present on all nucleated cells.  They destroy virally infected cells and tumour cells 
and are implicated in transplant rejection6.  CD8+ cells can be inactivated by certain molecules 
such as IL-10 and adenosine secreted by Treg cells.  This forces the CD8+ cells into an anergic 
state with prevents uncontrolled proliferation of immune cells and helps prevent autoimmune 
diseases. 
1.1.2.2 CD4+ T cells 
 
“Helper” T cells or CD4+ T cells are essential in the co-ordination and amplification of an 
effective immune response to foreign contaminants as they regulate both humoral and cellular 
immunity 1.  Cytokines excreted from the cells activate macrophages; promote inflammation; 
and stimulate the proliferation and differentiation of other T and B lymphocytes (Figure 2). 
 
Differentiated effector CD4+ cells appear 3-4 days after infection, the best known being Th1 and 
Th2 - differentiated only in the type of cytokine they produce7. Th1 cells secrete Interferon-y 
(IFNγ), a potent stimulator of macrophages and the production of antibody isotopes that 
promote phagocytosis of microbes. Th2 CD4+ leukocytes secrete interleukin (IL)-4, a cytokine 
that stimulates the production IgE antibodies from B cells, and IL-5 which activates eosinophils 
– therefore promoting phagocyte-independent, eosinophil-mediated immunity useful for 
targeting parasites. A fraction become long-lived memory T cells. 
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Figure 2. The co-ordination of cell-mediated and humoral immunity.  T Helper cells co-ordinate 
immunity through release of cytokines that stimulate B cells and cytotoxic T cells.  Cytokines also function in 
an autocrine fashion to reinforce activation8. 
 
The importance of the CD4+ T cell phenotype can be illustrated by the deleterious affects the 
HIV virus has on the immune system: the HIV virus targets cells that express the CD4 surface 
protein. The subsequent decrease in CD4+ T cell population increases the number of pathogens 
that escape antigen recognition. As a consequence there is an inflation in the number and 
severity of infectious diseases in the individual 9. 
1.1.3  T CELL ANTIGEN ACTIVATION 
 
T cells are unable to recognize free pathogens in the circulation.  A pathogen must first be 
processed and “presented” to a T cell by an antigen-presenting cell (APC)1.  T cell antigen 
activation requires the complexing of a T cell and an APC via the interaction of a series of 
proteins on the surface of both cells that include either the MHC type I (MHCI) or type II (MHCII) 
molecules on the APC; the TCR complex; and either the CD4 or CD8 molecule on the T cell. The 
APC displays antigen molecules on its surface via the MHC molecules to which a CD8+ or CD4+ T 
cell are able to recognize and initiate a response.  An endogenous antigen is displayed by MHC I 
and an exogenous antigen is displayed on MHCII. 
  INTRODUCTION 
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1.1.3.1 Antigen-Presenting Cells 
 
APCs are highly efficient at internalizing antigens, either by phagocytosis or by receptor-
mediated endocytosis10. APCs capture microbial cells (typically viruses or bacteria) then travel 
from the infection site to the lymph nodes where the internalized microbe is digested and 
antigen fragments called epitopes are displayed on the MHC molecule on the surface of the cell 
for T cell activation and clonal expansion (Figure 3) 1. Cells that express both MHC proteins are 
often termed “Profession APCs”10.  For example, DCs  are one of the most important professional 
APCs and express a wide range of antigen presentation11.  A DC, or any cell in the body, that 
becomes infected by a virus may promote its own self-destruction via a cytotoxic T cell by 
expressing part of the infected cell through the ubiquitously expressed MHCI complex.  
However, DC can also promote an immune response via the MHCII proteins and interaction with 
CD4+ helper T cells.  Other types of professional APCs include macrophages, B cells, and some 
epithelial cells. 
 
 
 
Figure 3. Antigen presentation via Major Histocompatibility Complex I & II and recognition by T Cell 
Receptors. 1. Antigen associates with MHC molecule; 2. T cell recognizes MHC/Antigen combination12.  
 
1.1.3.2 T cell antigen receptors 
 
The T cell antigen receptor (TCR) is a heterodimer that exists bound to the cell membrane in 
complex with another protein complex, the CD3 molecules.  The TCR consists of two variable (α) 
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alpha and beta (β) chains; the CD3 complex has four distinct chains (a CD3 γ, CD3 δ and two 
CD3ε chains)13 – together these molecules form the TCR/CD3 complex.  The alpha and beta 
chains of the TCR have a constant (C) region and a variable (V) region.  The extracellular 
variable region binds to the antigen/MHC complex while the constant region anchors the TCR to 
the cell membrane.  As mentioned, during antigen encounter the CD4 and the CD8 molecules 
work as co-receptors stabilising the interaction between the TCR and the MHCII or MHC I 
surface molecules.   A random process of gene splicing and rearrangement of the segments of 
DNA that code for the antigen-binding parts of the TCR accounts for the infinite range in antigen 
specificity 2.  A fully developed population of T cells contains in excess of approximately 1 
trillion unique T-cell receptors, which are rearranged and selected for in the thymus. This 
almost infinite specificity means that upon antigen encounter only one T lymphocyte will be 
activated and start to proliferate.  This process is called clonal expansion.   
1.1.3.3 Some molecules involved in T cell activation 
 
T cell activation requires two separate signals1. The first is the binding and recognition by the 
TCR to antigens presented by an APC via the MHC. The second signal occurs upon co-stimulation 
of the CD28 molecule which is expressed constitutively by naïve T cells. The ligand for CD28 is 
the CD80 protein on the APC. This second, co-stimulatory signal ensures that the cell reacts to 
foreign contaminants only and strengthens the bond between the two cells1.  Another 
interaction between the adhesion molecules integrin protein LFA-1 on the T cell and ICAM on 
the APC, further strengthen the bond during T cell activation13.  TCR-antigen recognition 
activates SRC kinase Lck which phosphorylates the immunoglobulin family tyrosine (Y)-based 
activation motifs (ITAMs) in the CD3 protein complex14(figure 4).  The subsequent 
phosphorylation of chain associated protein (ZAP70) leads to the phosphorylation of other 
protein tyrosine kinases (PTKs), increased endogenous Ca2+ flux and RAS activation.  These 
upstream events lead to a complex series of signaling cascades crucial for a normal immune 
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response that lead to the activation of transcription factors, production of the late phase T cell 
specific growth factor IL-2 and subsequent clonal expansion15. 
 
 
Figure 4. Events following TCR activation. The T-cell receptor (TCR) and CD4 or CD8 co-receptors 
recognise the major histocompatibility complex (MHC) (not-pictured).  Ligation activates the SRC kinase Lck 
(purple) which phosphorylates immunoglobulin family tyrosine Y-based activation motifs (ITAMs) in the 
CD3 protein complex (Brown – Y-p).  Subsequent recruitment and phosphorylation of chain-associated 
protein (ZAP70) leads to a series of complex signalling cascades leading to, PI3K/Akt activation (green) and 
increased calcium (Ca2+) flux, activation of transcription factors, cytokine production and proliferation16. 
 
 
1.2  CELLULAR METABOLISM 
 
Indeed, what happens internally after TCR/CD3 activation is a classic example of a cell adapting 
to its environment by the rewiring its metabolic pathways17.  This metabolic shift from one state 
to another allows the cells to grow and replicate and, ultimately, serve their function to 
eliminate foreign pathogens.  It also presents a challenge: how to effectively take up and 
metabolize the nutrients necessary for optimal cellular growth and replication. 
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Metabolism defines the complex network of chemical reactions that allows organisms to convert 
substances into metabolic energy, and biomolecules necessary for daily maintenance in addition 
to growth and proliferation 18. 
 
The conversion of one substance into another is achieved by a series of reactions commonly 
called metabolic pathways 19.  For example, proteins ingested by an organism are commonly 
broken down into the amino acids that fuel in vivo protein synthesis.  However, amino acids can 
also be converted into numerous nitrogen-containing substances including nucleotides20.  In 
addition, amino acids are also converted into molecules containing sulphur groups such as 
Acetyl Coenzyme A (AcCoa): a molecule vital to energy metabolisms and to the antioxidant 
glutathione (GSH) that protects  cells from damage.  Each step in these series of reactions 
requires an enzyme which allows the metabolic reactions to occur in a regulated fashion. 
 
This regulatory ability is of most importance for the production of energy.  Energy is supplied by 
adenosine triphosphate ATP - a high energy molecule that fuels the reactions that allow muscles 
to contract, in addition to the numerous biosynthetic reactions that fuel cellular growth and 
replication18.  Glucose derived from dietary and internal stores of carbohydrates (glycogen in 
animals), amino acids from protein, and fatty acids all contribute to the production of ATP 
through interrelated metabolic pathways (Figure 5).  
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Figure 5.  Energy substrates converge on TCA cycle. The catabolism of the carbohydrate glucose, amino 
acids from proteins and fatty acids from fat produce Acetyl CoA which can be further oxidized in the 
Tricarboxylic Acid Cycle (TCA or Krebs cycle) in the mitochondria21.  
 
All three metabolic pathways (of glucose, lipids and some amino acids) converge on 
mitochondrial molecule Acetyl CoA, a key substrate fed into a series of amphibole reactions, also 
called the citric acid cycle, or tricarboxylic acid (TCA) cycle18.  The reactions in the TCA cycle 
supply the carbon intermediaries needed during the anabolism of numerous biomolecules and 
the synthesis of ATP.  ATP is produced by oxidative phosphorylation by the reducing agent 
nicotinamide adenine dinucleotide (NADH) and flavide adenine dinucleotide (FADH) at the 
inner membrane of the mitochondria22.  Here molecular oxygen (O2) is reduced to water in the 
presence of H+ and electrons from supplied by NADH and FADH.  For a simplification see  
Figure 6.  
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Figure 6. Production of ATP from glucose. Acetyl CoA is catabolized in the TCA cycle to produce CO2 and 
reducing agents for the production of ATP in the mitochondrial matrix membrane23.  
 
The energy requirements of cells can change exponentially from moment to moment, depending 
on the local and systemic requirements17;24.  To meet such requirements flux through the 
various metabolic pathways changes rapidly by, for example, regulating the activity of a single, 
or set of, enzymes in a chosen pathway.  This type of dynamic switch in metabolic activity is well 
illustrated when a naïve quiescent T cell is activated, resulting in growth and proliferation. 
1.2.1  T CELL METABOLISM 
1.2.1.1 Naive T cells 
 
Naive T cells roam the circulation in search of pathogens17.  As such their metabolic needs are 
relatively modest, needing only sufficient ATP to fuel migration and basic housekeeping duties 
such as maintaining membrane ion gradients and the cytoskeleton, synthesis of biomaterials for 
cell maintenance, and transportation of proteins and other substrates around the cell.  They 
achieve this mainly through the highly efficient catabolism of glucose and other intermediaries 
through the TCA cycle and mitochondrial oxidative phosphorylation (as described above)25.  
Naive T cells are not autonomous but are dependent on extrinsic signals in order to maintain 
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this basic metabolic profile 26.  A lack in these signals renders the cells unable to adequately 
absorb glucose and the cells atrophy and die 27.   
1.2.1.2 Proliferating T cells 
 
Within minutes after activation, T cells undergo dramatic physiological changes.  This can be 
observed by cell swelling (blastogenesis) during the first 24 to 72 hours post activation28.  This 
increase in size is supported by elevated uptake of several energy substrates necessary for the 
increased synthesis of biomass consisting of DNA, proteins and lipids25;29-32.  Synthesis of 
biomass also requires ATP and the electron donor NADPH.  Figure 7 (below) shows the massive 
shift in metabolic activity associated with the production of protein, lipids and ATP in activated 
lymphocytes. 
 
 
Figure 7. Increased biosynthesis of proteins, lipids and energy production upon T-cell activation33. 
 
The release of cytokines and the up-regulation of several transcription pathways such as the 
janus-kinase and Phoshatidylinositide 3-kinases /  serine-threonine-specific protein kinase 
(PI3K/Akt) pathways, mediated by the c-Myc proto-oncogene further enhance and prime the 
cell for expansion17.   
 
Activated T cells produce the T cell-specific growth factor IL-2 which further stimulate adjacent 
T cells to up-regulate their IL-2 receptor (IL2R) as well as the glucose transporter GLUT1 for 
increased uptake of glucose, both in order to support proliferation34.  Downstream from the IL-
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2R, the PI3K-Akt transcription pathway potentiates the up-regulation and translocation of Glut1 
to the cell membrane; increases the up regulation and localisation of hexokinases and other 
glycolytic enzymes such as phosphofructo kinase 1 (PFK1) and lactate dehydrogenase ( LDH); 
increases flux through the pentose phosphate pathway (PPP); and activates the mammalian 
target of rapamycin (mTORC1) pathway vital for protein synthesis – thus ensuring maximum 
uptake, retention and utilization of glucose within the cell and initiation of protein synthesis 
(Figure 8)35-37.   
 
 
 
Figure 8. Metabolic reprogramming in activated T cells. The indicated metabolic activities in resting T 
cells (black bars) and activated T cells (white bars).  The shift was determined 24 hours post activation by 
increased glycolysis, pentose phosphate pathway activity, glutaminolysis and oxygen consumption, with 
concurrent reduced activity in the TCA cycle and fatty acid oxidation33. 
 
AMP-activated Protein Kinase (AMPK) is a vital regulator of energy metabolism in cells18;38.  It 
functions by increasing the activity of catabolic, ATP-generating pathways and inhibiting 
anabolic processes that deplete ATP.  AMPK traditionally responds to an increasing intracellular 
AMP / ATP ratio which indicates falling cellular energy levels and by phosphorylation of Liver 
kinase B1 (LKB1) at Threonine 172.  However AMPK has been shown in expanding T 
lymphocytes to respond to elevated Ca2 levels through Calcium-calmodulin-dependant protein 
kinase kinases (CaMKKs)(Figure 9)39.  TCR activation evokes the release of Ca2 from the 
endoplasmic reticulum in addition to Ca2 entry via membrane ion channels.  A sustained, 
elevated intracellular Ca2 concentration is vital during the early stages of T cell activation, 
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especially for the production of cytokines. In non-proliferating cells AMPK functions to promote 
ATP production and conservation by promoting ATP-producing processes and down-regulating 
catabolic processes.   However, in expanding lymphocytes AMPK responds to this initial calcium 
stimulus and functions to “prime” T lymphocytes for the demands of the energy-intensive 
processes during activation and expansion by accelerating ATP production in anticipation of 
increased demand.   
 
 
Figure 9. Activated T cells prepare for increased energy demand by activation of AMPK and 
increased uptake and consumption of glucose.  (A) AMPK activation by TC-induced R activation of 
CaMKK2. (B) Immediately after TCR activation AMPK up-regulation contributes to increased ATP production 
through oxidative phosphorylation, followed by increased synthesis and translocation of Glut1 to the 
membrane for increased glucose uptake and glycolysis40.  
 
1.2.2  GLUCOSE METABOLISM IN T CELLS 
 
In resting mature lymphocytes glucose utilisation is divided almost evenly between lactate 
production (glycolysis), synthesis of oligosaccharides (glycosylation), and oxidation to carbon 
dioxide (glycolysis, TCA cycle and mitochondrial oxidative phosphorylation)32. Activated T cells, 
however oxidize the majority of the glucose to pyruvate through glycolysis and then to lactate 
by lactate dehydrogenase (LDH) where it is then excreted from the cell (see figure 9)32;34;37;40-42 . 
This shift to aerobic glycolysis, also known as the Warburg effect (named after its discoverer), is 
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elevated and sustained during expansion and differentiation and occurs even in the presence of 
ample amounts of oxygen43.   
 
At first glance this shift to a less efficient production of ATP seems counterintuitive to the 
energy demands of proliferating cells: the oxidation of glucose through aerobic glycolysis 
produces only 2 molecules of ATP whereas 36 ATPs are generated through mitochondrial 
oxidative phosphorylation18.  Yet many single-celled organisms use glucose fermentation to 
proliferate, demonstrating that aerobic glycolysis is sufficient in providing the necessary ATP 
for cellular replication.  This perceived inconsistency in energy production may be due to our 
over-estimation of a cell’s energy requirements under proliferation.   Normal proliferating cells 
are exposed to an abundant supply of glucose and nutrients and despite tremendous rates of 
replication consistently exhibit high ratios of NADH/NAD and ATP/ADP, suggesting that the 
demands of the proliferating cell extend far beyond mere energy production24.  A proliferating 
cell must replicate all of its contents.  This replication places large demands on the supply of 
macromolecule precursors (lipids, amino acids, nucleotides and reducing agents (such as 
NADPH).  Glucose (and glutamine, discussed in the next section) provides, almost exclusively, 
the carbon backbones necessary for this synthesis through anabolic pathways: the PPP and the 
production of the sugar metabolite ribose 5-phophate necessary for nucleotide synthesis (not 
pictured), and NADPH which is also necessary for the maintenance of reduced GSH in addition 
to macromolecule synthesis; fatty acid synthesis from Acetyl CoA; and glycolytic intermediaries 
for synthesis of non-essential amino acids (NEAA) (see figure 10)28;44.  It quickly becomes 
apparent that committing the majority of glucose to oxidative phosphorylation and 
mitochondrial ATP synthesis would severely restrict production of these intermediaries and 
retard cellular replication28. 
  INTRODUCTION 
23 
 
 
Figure 10.  Flux of glucose and substrates in quiescent and proliferating cells. Flux of glucose (glc) in a 
quiescent cell (left) through glycolysis into pyruvate (pyr) which is then oxidised in the TCA cycle.  Other 
oxidisable substrates like amino and fatty acids can also be converted into TCA intermediaries.  Here the 
majority of ATP (yellow stars) is produced by oxidative phosphorylation.  During proliferation (right), ATP 
generation is due largely to the massive increase in glycolytic flux.  The resulting pyruvate is converted into 
lactate (lac) by lactate dehydrogenase (LDH) which regenerates NAD+ from NADH necessary for glycolysis.  
The resulting lactate is excreted from the cell.  Some pyruvate enters the mitochondria to be converted to 
acetyl-CoA by pyruvate dehydrogenase (PDH) which is then converted into other TCA intermediaries such as 
citrate (cit), essential in the generation of lipid membranes for daughter cells. Amino acid pre-cursors from 
the TCA cycle also contribute to the synthesis of proteins in the cell. In the cytoplasm citrate is hydrolysed by 
ATP citrate lyase (ACL) into acetyl-CoA for synthesis of lipids by fatty acid synthase (FAS).   Malate 
dehydrogenase (MDH) converts the resultant oxaloacetate into malate (mal) which can then either by 
transported back to the mitochondria for conversion back to pyruvate by malic enzyme (ME) whilst 
generating NADPH used in the synthesis of fatty acids24. 
 
Of perhaps equal importance as a major provider of carbon backbones for this increase in 
biomass by proliferating T cells is glutamine.   
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1.2.3  GLUTAMINE METABOLISM  
 
Glutamine is the most abundant amino acid in the human body comprising 60% of free amino 
acids45.  It is synthesised primarily in the lungs, skeletal muscle and adipose tissue.  Serum 
concentrations range from 0.4 - 0.9mM46.  It is synthesized through the conversion of glutamate 
and ammonia to glutamine through the hydrolysis of ATP: 
 
L-Glutamate + NH3 + ATP > L-Glutamine + ADP + Pi 
 
Glutamine is the primary supplier of nitrogen and carbon for protein synthesis; it is essential in 
the transportation and regulation of nitrogen; vital in the production of nucleotides, glucose 
through gluconeogenesis, and glucosamine; as a precursor in the synthesis of 
neurotransmitters; acid/base regulation in the kidneys; and in the replenishing of GSH for 
optimal protection against oxidative stress47;48.  It is also the major provider of carbon for alpha-
ketoglutarate and an important anaplerotic substrate for the TCA cycle and the synthesis of 
lipids (Figure 11).  Indeed, many highly proliferative tissue types exhibit elevated levels of 
glutamine turnover to support energy production including enterocytes, fetal cells, hair follicles, 
tumours and the cells of the immune system46. 
 
Activated T cells selectively enhance glutamine uptake through expression and synthesis of the 
major glutamine transporters Sodium-coupled amino acid transporters 1 and 2 (SNAT1 and 
SNAT2), Solute carrier family 7 member 5 (SLC7A5) and Neutral amino acid transporter 
(ASCT2).  Elevated glutamine uptake and metabolism is stimulated by TCR-CD3 induced 
ERK/MAPK activity and increased c-myc expression 30;30;49.    
 
  INTRODUCTION 
25 
 
 
 
Figure 11. Catabolism of glutamine in proliferating cells. Citrate lost to the synthesis of lipids (green 
arrows) in proliferating cells is replenished from the metabolism of glutamine (red arrows).  After transport 
into the cytosol by SNAT glutamine (Gln) donates nitrogen for purine and pyrimidine synthesis through 
oxidation to glutamate (Glu) by Glutaminase (GLS).  Glutamate donates its amino group to α-keto acids for 
synthesis of nonessential amino acids and α-ketoglutarate (α-KG).  Mitochondrial glutamine can also be 
converted into glutamate by phosphate-dependent Glutaminase (PDG) which frees an amido group (red 
square).  The mitochondrial glutamate can then either be used to synthesize amino acids by 
aminotransferases or mitochondrial α-KG by glutamate dehydrogenase (GDH).  α-KG can then enter the TCA 
cycle and replenish oxaloacetate (OAA) and citrate.  The carbon from glutamine can also be converted into 
lactate (glutaminolysis) which generates the reducing agents NADPH and NAD+ in the cytoplasm24. 
 
As figure 11 demonstrates, glutamine is a key anaplerotic source of carbon for replenishment of 
TCA intermediaries and synthesis of macromolecules.  It is also a source of fresh NAD+ and 
NADPH necessary for reductive, biosynthetic pathways.  In glioblastoma cells 90% of glucose 
and 60% of glutamine is converted into either lactate or lanaline which is then rapidly excreted 
from the cell, with robust NADPH production being the result50.  Inhibition of LDH, a key enzyme 
in this process, undermines cell proliferation.  This suggests that the removal of excess carbon 
from the cell may be necessary to generate enough NADPH to fuel cell proliferation51. 
 
As mentioned earlier, GSH is the cell’s major antioxidant and its synthesis is dependent on 
adequate supply of glutamine.  GSH’s role is crucial in preventing oxidative damage to DNA, 
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proteins, enzymes and lipids52.  It is also an essential component in the synthesis and repair of 
DNA, enzyme activation and protein synthesis – all critical under rapid cell proliferation.  GSH is 
synthesised from the amino acids cysteine, glycine and glutamate.  Due to this dependence on 
glutamate, GSH synthesis is also highly dependent on adequate cellular glutamine.  Restricting 
available GSH to proliferating lymphocytes greatly diminishes their ability to replicate53.  
1.2.3.1 Glutaminase 
 
Glutaminase catalyses the hydrolysis of glutamine to glutamate and ammonia: 
 
  L-glutamine + H20 > L-glutamate + NH4 
 
Three mammalian Glutaminase isoforms have been identified: the Kidney-type Glutaminase 
(KGA) and Glutaminase C (GAC) - a splice-variant of KGA - both coded by the gls gene; and Liver-
type Glutaminase (LGA) - coded by gls2.   KGA and GAC are expressed in the brain, kidney, 
intestine, fetal liver and many other tissues, unlike LGA, which, as the name suggests, is located 
only in hepatic cells46.  Evidence points to the binding of both KGA and GAC to the inner 
membrane of the mitochondria, however some evidence suggests they may reside in the 
intramembrane, free from the membrane54;55. Figure 12 depicts the identical N-terminus shared 
by KGA and GAC and the identical core shared by all variants that is highly conserved in each 
isoform and likely the catalytic domain of the enzyme.   Each enzyme has a unique C-terminal. 
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Figure 12. The three human glutamines isoforms are compared to bacterial Glutaminase.  A common 
core (black) is conserved in each isoenzyme.  GAC and KGA isoforms share an identical N-terminal (white).  
Each human Glutaminase isoform has a unique C-terminal (patterns)56. 
 
The three different isoenzymes vary not only in protein structure but also in enzyme kinetics. 
GAC and KGA isoforms require a polyvalent anion for activation, the most common being 
phosphate which elicits half-maximal activity at 20-30mM46.  The isoforms have Km values for 
glutamine at around 2-5mM.  The Km values for both enzymes are improved in the presence of 
elevated phosphate30.  This is in contrast to LGA which has a relatively high Km for glutamine (17 
mM) and hence much less sensitive to variations in the concentration of phosphate.  Both KGA 
and GAC, but not LGA, are inhibited by their enzymatic product glutamate. 
 
Reinforcing the notion that fast-growing cells are reliant on increased levels of glutamine, many 
cancer cells up-regulate the KGA and GAC isoforms for continued expansion, with mRNA levels 
elevated in breast cancer, colorectal carcinomas, adenomas and glyomas29.   
1.2.3.2 Glutaminase inhibitors 
 
Recently, attention has been focused on the ability of two compounds found to inhibit 
mammalian Glutaminase activity in vitro and in tumour cells57-59.  
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Figure 13. BPTES (Bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl) ethyl sulphide) 
 
 
Figure 14. Compound “968” (5-(3-bromo-4-(dimethylamino) phenyl)-2,2-dimethyl-2,3,5,6-
tetrahydrobenzo[a]phenanthridin-4(1H)-one) 
 
Both compound Bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl) ethyl sulphide (BPTES) (figure 
13) and 5-(3-bromo-4-(dimethylamino) phenyl)-2,2-dimethyl-2,3,5,6-
tetrahydrobenzo[a]phenanthridin-4(1H)-one (968) (figure 14) appear to allosterically regulate 
the Glutaminase enzyme by altering the tetramer confirmation59.  This differs to other 
Glutaminase inhibitors such as 6-Diazo-5-oxo-L-norleucine (DON) and acivicin which covalently 
modify residues on the binding pocket and have significant toxicity issues.  Both inhibitors are 
neither irreversible nor competitive versus glutamine and simultaneously lower both Km and 
Vmax values58.  It appears that 968 has a reduced ability to inhibit the phosphate-activated 
Glutaminase, whereas BPTES can, hinting at differing modes of inhibition for each compound.   
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Both KGA and GAC Glutaminase isoforms are elevated in certain tumour cells60.  Recent research 
has shown that inhibition of the GAC enzyme by compound 968 in these tumours can inhibit 
oncogenic progression59. 
1.3  AIM OF THE STUDY 
 
Based on what has been described above we hypothesize that the proliferative phenotype of 
increased glucose and glutamine dependency seen in many different cancer cells is similar in 
activated mammalian T lymphocytes , a view which is supported by the literature28;29;41;50;61.  
The enzyme Glutaminase is of particular interest because of it essential role in the catabolism of 
glutamine for anaplerotic carbon and reducing agents vital to cell proliferation.   
The primary aims for the study, therefore, are as follows: 
 Identification of protein and mRNA expression for Glutaminase in naïve non-
proliferating and CD3/CD28-activated proliferating CD4+ T lymphocytes. 
 Investigate the requirement of glutamine for T cell proliferation by selective inhibition 
of Glutaminase and by glutamine removal.  
 Investigate the intracellular concentrations, and flux of glutamine, in proliferating CD4+ 
T lymphocytes 
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2.0   METHODS 
 
A complete list of solutions and reagents can be found in Appendix B. 
 
2.1  CD4+ T Cell Isolation 
 
Human CD4+ T lymphocytes were isolated from buffy coats (supplied from Blodbanken, Ullevål 
sykehus).  Buffy coats are samples of anti-coagulated blood rich in leukocytes and platelets after 
density gradient centrifugation of whole blood samples.  Average volume was approximately 
40-50ml.  Buffy coats were diluted with 24ml cell medium (RPMI 1640: 10% inactivated FBS 
(fetal bovine serum); 2mM L-glutamine; 0.5% Penicillin-Streptomycin) and 1ml EDTA 
(Ethylenediaminetetraacetic acid) and rotated for 15min at 4 °C to prevent coagulation.   
 
Dynabeads CD4+ Isolation 
The Dynabeads CD4 Positive Isolation Kits (Invitrogen) were used to isolate CD4+ T 
lymphocytes from buffy coats.  The Dynabead vial was first vortexed for 30 seconds, then 200uL 
of the super paramagnetic bead solution (4.5 µm diameter; 4 x 108 beads/mL) was suspended in 
a Dynamag-2 magnet (Invitrogen), the supernatant removed, and the bead pellet washed with 
1ml PBS (phosphate buffer solution) at room temperature to remove the 0.02% sodium azide 
preservative.  The beads were then resuspended in 200uL cell medium and then added to the 
buffy coat solution which was then rotated at 4 °C for a further 30 minutes to allow bead/cell 
binding.  The bead-bound cells were then removed from the buffy coat solution by dispending 
the solution into two 50ml Falcon conical tubes and suspending these in a DynaMag-50 magnet 
(Invitrogen) for 5 minutes to allow the bead-bound cells to migrate and adhere to the side of the 
tube.  The buffy coat supernatant was then gently removed and discarded.  The resulting 
bead/cell deposit was then collected into one 15ml Falcon tube using 5ml PBS, then placed in a 
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Dynamag-5 (Invitrogen) for 2 minutes.  This step was repeated 4 times to wash the bead-bound 
CD4+ T lymphocytes and remove any impurities.  The cell pellet was then suspended in 100uL 
DETACHaBEAD solution (Invitrogen) and incubated for 1 hour at room temperature with gentle 
mixing.  The DETACHaBEAD solution contains a polyclonal anti-Fab antibody that releases the 
CD4+ cells from the Dynabeads.  After 1 hour the solution was vortexed at 2500rpm/min for 10 
seconds and placed in a magnet for 1 minute.  The supernatant containing the released CD4+ 
lymphocytes was then transferred to a fresh 15ml tube.  The remaining beads were then 
washed with 1ml PBS and then placed back on the magnet where the supernatant was removed 
and added to the fresh tube.  This step was repeated twice to salvage any residual cells. The 
resulting 2-2.5ml suspension was then placed in the magnet for a further 2 minutes to remove 
any remaining beads then centrifuged for 7 min at 1500rpm after which the supernatant was 
discarded  The cell pellet was then washed in 5ml PBS then centrifuged again for 7 min at 
1500rpm.  After discarding the supernatant the cell pellet was suspended in 1ml of cell medium 
(described earlier) and the cells were counted using a Biorad TC10 Cell Counter (isolation using 
this method yielded on average 50 million CD4+ lymphocytes) and incubated in cell medium at 
a concentration of 5 million cells/ml and stored (if not used immediately) in a cell incubator at 
36.5°C; 5% CO2.  
2.2  Identification of Glutaminase isoforms in resting CD4+ cells 
 
Western blots were used to characterise the relative levels of the Glutaminase isoenzymes in 
resting mature CD4+ lymphocytes.   
 
Lysation of cell pellet 
To effectively lyse the CD4+ cell membrane a solution containing 100uL of NP40 lysis buffer 
(Novex), 1uL protease inhibitor phenylmethanesulfonylfluoride (PMSF; 100x; Sigma) and 1uL of 
protease inhibitor cocktail (100x; Sigma) were added to the cell pellet and resuspended several 
times.  The solution was left on ice for 15 minutes with occasional vortexing (once every 3 
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minutes; 2500rpm/min).  To release the mitochondrial Glutaminase enzymes this procedure 
was supplemented with sonication (amplitude 60%; 6 seconds: 2x 2 second bursts).  The twice-
lysed cell solution was then centrifuged (15000RPM; 1 minute).  The supernatant was then 
removed, and, if not used immediately, snap frozen by suspending the supernatant in a -78°C 
ethanol/dry ice solution and then stored in a -80°C freezer.   
 
Protein concentration 
See Appendix C for a complete list of protein concentrations.   
 
Nanodrop 2000c Spectrophotometer 
Proteins in solution absorb ultraviolet light at wavelengths peaking at approximately 280nm.  
The NanoDrop 2000c Spectrophotometer (Thermo Scientific) was initially used for protein 
concentration measurements.   Two uL of the NP40 lysis buffer were pipetted onto the 
measurement pedestal of the Nanodrop 2000c and a BLANK reading was initiated using the PC 
software (Group: Classic; Protein A280).  The pedestal arm was raised and the sample wiped 
from the upper and lower pedestals using a lint-free laboratory wipe.  Next, 1-2uL of the CD4+ 
lysate was pipetted onto the lower pedestal, the sample named in the PC program and a 
measurement initiated.   A spectral image was reviewed to assess sample quality – a density 
peak should form at 280nm wavelengths with sufficient protein.  The measurements were 
repeated for all samples and data exported to excel. 
 
Pierce BCA Protein Assay 
Protein measurement was later performed using the Pierce BCA protein assay (Thermo 
Scientific).  This method was used on selected samples as high NP40 buffer has relatively high 
A280 absorbance along with other non-protein components such as nucleic acids and insoluble 
cell lysates which also absorb UV light at 280nm.  Together this contributed, in some cases, to 
unreliable and inconsistent measurements using the A280 method in the Nanodrop 2000c 
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Spectrophotometer (Thermo Scientific).  The BCA protein assay is based on bicinchoninic acid 
(BCA) and relies on two reactions: first, the peptide bonds in proteins reduce Cu2+ in proportion 
to the total amount of protein present in the solution, then the resulting Cu+ ions chelate with 
two molecules of bicinchoninic acid to form a purple-coloured product that strongly absorbs 
light wavelengths of 562nm.  The protein concentration can then be assessed by measuring the 
absorption characteristics of the target samples against protein solutions with known 
absorption characteristics.  The procedure for this assay can be viewed in Appendix A.  
 
Preparation of protein samples for polyacrylamide gel electrophoresis (PAGE) 
The Criterion Precast polyacrylamide gels (Biorad) come in various percentage densities of 
acrylamide.  The acrylamide density chosen is dependent on the size of the protein of interest: 
large proteins should be run in low-percentage acrylamide gels and small proteins should be 
run in higher percentage gels.  A 7.5% density gel was chosen because of the small size of the 
three Glutaminase isoforms (KGA: 73kDa; LGA: 66kDa; GAC: 55kDa).  Each well in the gel should 
hold the same amount of total protein.  This required the dilution of the higher-concentrate 
samples with the NP40 lysis buffer to standardize the concentrations.  Next, the lysate was 
mixed with 2x sodium dodecyl sulphate (2xSDS) sample buffer at 1:1 ratio (see Table 1 for a 
complete list of solutions).  The SDS solution binds to and uniformly charges the proteins in the 
sample so they can be separated according to relative size (and not charge).  The maximum well 
volume is determined by the number of wells in the gel and was taken into account when 
calculating lysate and SDS sample buffer volumes.  The SDS sample buffer/lysate mixture was 
heated for 5 minutes at 96 °C to denature the proteins. 
 
Loading samples 
A Criterion Precast Gel (Biorad) was placed in a Criterion Cell (Biorad) PAGE container prior to 
sample loading (see Table 2 for a complete equipment list).   The container was filled with SDS 
running buffer, including the reservoir at the top of the gel.  Potential bubbles at the bottom of 
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the gel were removed by lifting the gel a little upwards in the buffer once or twice.  The first well 
was loaded with 10uL Precision Plus Dual Colour (Biorad) protein standard (not heated).  The 
boiled samples were loaded carefully into the other wells with a pipette.  
Table 1. List of solutions  
Solutions Components 
SDS Running Buffer 
Transfer Buffer 
TBS (10x) 
TBST 
Blocking Buffer 
Primary Antibody 
Secondary Antibody 
150 g Tris, 720 g Glycine, 50 g SDS, dH2O up to 5 L 
15 g Tris, 72 g Glycine, 1 L (20%) methanol, dH2O up to 5 L 
12.11 g Tris, 58.4 g NaCl, pH 7.5 
1/10 10x TBS + 9/10 dH2O , 0.1% Tween 20 
5% non-fat dry milk powder in 1x TBST 
Diluted in 1x TBST 
8.4 µl from a 40% glycerol antibody solution to 10 mL of 1x TBST 
 
Table 2. List of equipment 
Equipment Manufacturer Catalog # 
Criterion 12+2 well 7.5% Precast gels 
Criterion 18 well 7.5% Precast gels 
Criterion Cell 
Criterion Blotter 
Criterion Filter Paper 
Criterion Foam Pad 
Biorad 
Biorad 
Biorad 
Biorad 
Biorad 
Biorad 
345-0005 
345-0006 
135BR 
560BR 
170-4085 
170-4086 
 
Electrophoresis 
The electric current generated by the PAGE cell forces the negatively charged protein samples to 
migrate through the acrylamide gel from the negative to the positive electrodes, where they 
fractionate according to size.  After loading the wells, the PAGE container was run with a Biorad 
Powerpac 300 at 100V for approximately 10 minutes until the samples had entered the gel 
properly, then at 130V until the dye had completely passed through the gel (typically 1 – 1.5 
hours).  
 
Protein transfer 
Once electrophoresis was completed the proteins were then transferred to, and immobilized on, 
a polyvinylidene fluoride (PVDF) membrane (Millipore).  The membrane is highly non-reactive 
and has a non-specific affinity for amino acids which makes it resistant to solvents and easily 
reused when examining other proteins.  First, the gel was removed from its plastic housing and 
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sandwiched in a sandwich holder (Biorad) next to a similar sized piece of PVDF membrane, 
compressed on either side by three 9.5x15.2cm Criterion Filter Papers (Biorad) and a Criterion 
Foam Pad (Biorad).  Care was taken to ensure gel viability and the eradication of air bubbles 
that would impede transfer.  The sandwich was placed in a Criterion Blotter (Biorad) container 
which was filled with transfer buffer and run overnight at 4 °C with a Biorad Powerpac 300 at 
15V for approximately 12-14 hours. 
 
Blocking 
Before probing with the appropriate antibody, the freshly blotted PVDF membrane was blocked 
to prevent any unspecific antibody binding: 1 hour at room temperature in blocking buffer (5% 
non-fat dry milk powder in TBST (Tris-Buffered Saline plus Tween 20) on a roller.  Milk 
contains many proteins that bind to the membrane and reduce non-specific binding.  After 
blocking the membrane was rinsed with TBST until the rinsing liquid was clear. 
 
Probing 
Primary antibodies used for detection are produced when a host animal is exposed to the 
protein of interest and the resultant antibodies harvested.  When exposed to the membrane-
bound protein the antibodies bind to the protein.  A secondary antibody is then directed at a 
species-specific segment of the primary antibody (i.e. mouse, rabbit, donkey).  The secondary 
antibody is linked to horseradish peroxidase which is subsequently used to cleave a 
chemiluminescent agent that produces light and can be detected by a light-sensitive camera to 
determine protein concentrations.   
 
The PVDF membrane was first cut into strips to allow incubation with the three Glutaminase 
antibodies plus the control (α-tubulin) and then incubated in the primary antibody solution 
(5ml TBST plus antibody) over night at 4°C on a roller.  After the primary incubation the 
membrane(s) was washed with TBST for one hour, changing buffer every 10 minutes.  
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Incubation with the secondary antibody (8.4uL from a 40% glycerol antibody solution to 10ml 
of 1xTBST) was 1 hour at room temperature, followed by the same washing procedure as for 
the primary antibody.  
 
Detection 
The probed and washed membrane were incubated with 1-5ml (dependant on number of 
membranes) of Reagent A (Lumino/Enhancer Solution) and B (Stable Peroxide Solution) from 
the Super Signal West Pico Chemiluminescent Kit (Thermo Scientific) and laid on a clear plastic 
sheet (e.g. Gladpack, gladwrap).  The membrane was then exposed using the G.BOX Chemi XL 
CCD system (SynGene) at 2 min intervals for 15 minutes to capture the image. 
 
Re-probing 
For re-probing, the membrane(s) were washed with TBST for 30 minutes to remove the 
chemiluminescent substrate then incubated with the Restore Western Blot Stripping Buffer for 
5 to 15 minutes at room temperature, washed in TBST for a further 30 minutes, blocked with 
blocking buffer (described previously) for 1 hour at room temperature and then re-probed. 
2.3  CD4+ T lymphocyte activation 
 
CD4+T lymphocyte activation assay 
Activation of CD4+ lymphocytes was performed in 24-well incubation plates (approx. 3 mill/ml 
for activated cells; and 5 mill/ml for control cells).  The cells were incubated in RPMI1640 
supplemented with glutamine and antibiotics (as described previously).  CD4+ cells were 
stimulated with 37.5uL Dynabead CD3/CD28 Expansion beads (Invitrogen; 4x107 cells/mL); the 
control cells received 22.5uL dummy beads - Dynabead Mouse T-Activator CD3/CD28 
(Invitrogen; 4x107 cells/mL).  All beads were washed with PBS to remove the preservative as 
described earlier.  IL-2 was added to all wells at a concentration of 30U/mL.  Total volume in 
each well was 1ml.  The plate was then incubated at 37°C / 5%CO2 for 72 hours in an incubator.    
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After 72 hours the well contents were then moved to 1.5mL Eppendorf tubes and centrifuged at 
high speed (15000RPM) for 10 seconds.  The supernatant was removed and the cell pellet 
washed with PBS, centrifuged again at high speed and, if not used immediately, snap frozen in a 
-78 °C ethanol/dry ice solution and stored in a -80 °C freezer. 
 
[3H]-Thymidine Incorporation 
A [3H]-Thymidine incorporation assay was performed to test for successful CD4+ lymphocyte 
activation.  3H-thymidine is a radioactive nucleoside that is incorporated into the newly 
synthesised DNA strands of the proliferating cells during mitotic cell division. The protocol 
above was adjusted to a 96 well plate/100uL volume assay using the same cell-to-bead ratio 
and activation with CD3/CD28 Dynabeads.  After incubation for 48 hours a 25uL solution of 
[3H]-Thymidine (40 uCi/mL; Nerliens) was added to each well.   After incubation for a further 
24 hours the cells were harvested using a Filtermate 196 Harvester (Packard) and the level of 
3H-thymidine incorporation into DNA then measured using a Top Count Microplate Scintillation 
Reader (Packard).   
7 day expansion assay 
Fifty ml of cell medium supplemented with IL-2 (30U/ml) was heated to 36.5°C and added to a 
150 cm2 Falcon Cell Culture Flask (BD Biosciences).  Approx. 50 million CD4+ lymphocytes were 
added to the mixture after isolation (see CD4+ lymphocyte isolation).  Eight hundred uL of 
Dynabeads CD3/CD28 Expansion beads (4x107 beads/ml; Invitrogen) solution was added to the 
lymphocyte culture (after washing; see CD4+ T lymphocyte activation assay) and gently 
resuspended with a 5ml pipette.  After four days the cells were gently resuspended once more 
and then split equally into two new 150 cm2 Falcon Cell Culture Flasks.  25ml of fresh cell 
medium supplemented with IL-2 was added to each flask and the flasks incubated for a further 
72 hours. 
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Glutamine removal  
To determine to what extent the level of glutamine in the cell medium had on CD4+ T 
lymphocyte activation Dynabead CD3/CD28 stimulation beads (Invitrogen) were used to 
stimulate CD4+ T lymphocytes in serial dilutions of glutamine ranging from 0.1 to 10mM. The 
FBS (fetal bovine serum) was dialyzed with a “Slide-A-Lyzer” Dialysis Cassette (30ml; 3.5K 
MWCO; Thermo Scientific) to remove small molecules including glutamine (for procedures see 
Appendix A). Then 100ul of a CD4+ T lymphocyte population (15x106 cells/ml) in cell medium 
(DM5030: 10% dialyzed, inactivated FBS (fetal bovine serum);  0.5% Penicillin-Streptomycin; 
IL-2  30U/ml; 36.5°C) were distributed in a 96-well curve-bottomed microplate and activated 
with 18.75ul Dynabeads CD3/CD28 Expansion beads (4x107 beads/ml; Invitrogen) per well 
(washed first, as described earlier). The microplate was then incubated at 36.5°C for 48 hours.  
25ul of 3H-Thymidine (40 uCi/mL; Nerliens) was then added to each well and then incubated 
for a further 24 hours.  Cells were then harvested and incorporation of 3H-thymidine was 
measured using a scintillation counter to determine rate of proliferation.  All tests were 
performed in triplicate. 
 
Glutaminase inhibition – CD4+ T Lymphocytes 
Two potential compounds were evaluated to disrupt cellular glutamine metabolism in CD4+ T 
lymphocytes at the level of Glutaminase (see Glutaminase Inhibitors).  An assay was set up to test 
whether introduction of these inhibitors would have an inhibitory effect on proliferation as had 
been observed in other highly proliferative cells.  The assay protocol was identical to the 
glutamine removal method described in the section above (minus the dialysing step, and 
supplementing the medium with 500uM L-glutamine).  In addition both compound 968 (SPECS) 
and BPTES (Drug Discovery Laboratory AS) were included in the assay. Due to precipitation 
issues both inhibitor stocks were made with 100% DMSO.  Serial dilutions of both inhibitors 
were made so that final assay concentrations were 0.1, 1, 10 and 100uM after addition of 0.5ul 
per well (max 0.5% DMSO per well).  Control wells (minus inhibitor, with DMSO) were included.  
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3H-thymidine incorporation was measured after 72 hours.  All tests were performed in 
triplicate. 
2.5   qPCR – Gene Expression 
 
Quantitative polymerase chain reaction (qPCR) was used to detect the gene expression levels in 
the naïve and activated CD4+ lymphocyte samples.  RNA was first extracted from target samples 
and then converted to cDNA using reverse-transcriptase reaction.  The cDNA templates were 
then exposed to gene specific probes and analysed using qPCR to determine relative expression 
levels. 
 
RNA isolation 
The RNeasy Plus Mini Kit (Qiagen) was used for RNA isolation from the naïve and activated 
CD4+ lymphocyte samples.  All work was performed on ice.  A buffer containing 1 part β-
mercaptoethanol to 100 parts RLT Plus buffer (from RNeasy Kit) was added to each sample 
(350uL per sample).  The RLT Plus buffer contains highly denaturing guanidine-isothiocyanate 
mix which inactivates RNases and ensures purification of intact RNA.  The CD4+ lysate/buffer 
solution was then homogenized with a syringe and needle (20 gauge/0.9mm diameter; approx. 
10 cycles was sufficient).  The homogenized solution was then spun through the gDNA 
Eliminator columns (30 seconds at 10000rpm), which in combination with the high-salt RTS 
buffer removes genomic DNA.  350uL of 70% ethanol was then added to the flow-through which 
was then transferred to an RNeasy spin column and centrifuged for 15 seconds at 10000RPM.  
During centrifugation the total RNA binds to the internal membrane and any impurities are 
washed away.  The flow-through was then discarded and 700uL RW1 solution (from RNeasy 
kit) was added to the RNeasy spin column and then centrifuged for a further 15 seconds at 
10000RPM.  The flow through was discarded again.  500uL RPE solution (from RNeasy kit) was 
then added to the spin column and centrifuged for 15 seconds at 10000RPM, after which the 
flow through was discarded once more.  This process was repeated twice to rinse any 
  METHODS 
40 
 
contaminants from the RNA collection membrane.  The column was then placed inside a 
supplied 1.5mL collection tube and 50uL of 60 °C RNA-free water was added directly to the 
membrane to elute the RNA.  The RNeasy Spin Column and collection tube was then jointly 
centrifuged at 10000RPM for 1 minute to collect the purified RNA. 
 
RNA concentration 
The NanoDrop 2000c Spectrophotometer (Thermo Scientific) was used to measure total RNA 
concentrations in the activated and non-activated CD4+ T lymphocytes.   The program was set 
to “Group: Classic” and “Nucleic Acid” in the home screen and to “RNA” analysis at the 
measurement screen.  First 2uL of the RNase-free water was pipetted onto the measurement 
pedestal of the Nanodrop 2000c and a BLANK reading initiated from the measurement screen.  
The pedestal arm was then raised and the sample wiped from the upper and lower pedestals 
using a lint-free laboratory wipe.  Next, 1-2uL of the purified RNA solution was pipetted onto the 
lower pedestal, the sample named, and a measurement initiated.   The process was repeated for 
all samples and the data exported to Excel.  All work was performed on ice.  The RNA 
concentrations were standardized for each sample with the addition of RNase-free water to the 
higher concentrates. (see Appendix C for a complete list of total RNA concentrations).   
 
Reverse Transcription 
Complementary DNA (cDNA) synthesis from the purified RNA samples was achieved using the 
QuantiTect Reverse Transcription Kit (Qiagen).  Reverse transcriptase enzymes are 
multifunctional, with 3 distinct enzymatic activates: an RNA-dependent DNA polymerase and 
DNA-dependent DNA polymerase transcribes cDNA from the RNA template; and an 
exoribonuclease then degrades the RNA.  These 3 steps allow for transcription of RNA into DNA 
for later detection.  The kit provides a two-step process that: 1) eliminates genomic DNA and; 2) 
synthesizes cDNA using a reverse transcriptase reaction. All work was performed on ice. 
1. Genomic DNA removal:  
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The genomic DNA elimination reaction was performed according to Table 3. 
Table 3. Genomic DNA elimination reaction components 
Component Volume/reaction Final Concentration 
gDNA Wipeout Buffer, 7x 
purified CD4+ RNA 
RNase-free water 
2ul 
(from Nanodrop 2000c) 
Variable 
1x 
Total volume 14ul - 
 
The elimination reaction was then incubated for 2 minutes at 42 °C and then placed back on ice.   
2.  Reverse transcription: 
The reverse transcription master mix was prepared according to Table 4. 
Table 4.  Reverse-transcription reaction components. 
Component Volume/reaction Final Concentration 
Reverse-transcription master mix 
Quantiscript Reverse Transcriptase 
Quantiscript RT Buffer 
RT Primer mix 
 
Template RNA 
Entire gDNA elimination reaction 
 
1ul 
4ul 
1ul 
 
 
14ul 
 
 
1x 
Total volume 20ul - 
 
Fourteen uL of the RNA template mix from the previous step is added to each PCR tube 
containing the reverse-transcription master mix and incubated in a thermal cycler for 15 
minutes at 42 °C; a further3 minutes at 95 °C and then at 4 °C before being placed immediately 
on ice.  A negative control (no reverse transcriptase; no-RT) was included to test for any 
contaminating genomic DNA.  This is done by performing a control reaction with no reverse 
transcription added. 
 
qPCR 
Quantitative polymerase chain reaction (qPCR) and TaqMan Gene Expression Assays (Applied 
Biosystems) were used to amplify and detect the specific nucleic acid sequences used to 
synthesise the three Glutaminase isoenzymes in the stimulated and non-stimulated CD4+ 
lymphocyte samples.  The TaqMan assays rely on the use of sequence-specific reporter probes 
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that emit a fluorescent signal when cleaved from the cDNA template during thermal cycling and 
the transcriptive action of DNA polymerase (see figure 15).   
 
Figure 15. RT-PCR with fluorescent probes. Polymerisation of the cDNA template cleaves the gene-specific 
TaqMan probe (purple) only if it is hybridized to the target sequence.  The probe fragments and the reporter 
(R – green) displaces, separating from the quencher (Q – blue).  The reporter emits a fluorescent signal 
which is detected by the RT-PCR equipment in real-time. (Image retrieved 20 March 2013, from: www SDS (sodium dodecyl 
sulphate).appliedbiosystems.com) 
 
After reverse transcription the TaqMan Gene Expression assay reagents were thawed on ice and 
combined with the cDNA templates in a 96 well PCR microplate according to Table 5 (below).  
Purified water was added to each cDNA template if greater volumes were required.   
Table 5. qPCR gene expression reaction components 
Component Volume/reaction Final Concentration 
TaqMan Master Mix PLUS  
TaqMan Assay  (10:1) 
cDNA template 
 
11ul 
9ul 
 
2x 
 
Total volume 20ul  
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The reaction mix was then centrifuged for 1 minute at 1200rpms and the microplate placed 
inside an Applied Biosystems 7900HT Fast Real-Time PCR system with the thermal cover 
attached.  The system was set to determine relative DNA levels (∆∆ct (RQ)); detectors were 
added according to the plate setup and samples labelled.   Thermal cycling was set as per  
Table 6. 
Table 6.  PCR Thermal cycling settings 
 
Incubation 
Enzyme 
activation 
PCR 
Step HOLD HOLD CYCLE (40 Cycles) 
   Denature Anneal/Extend 
Time 2 min 10 min 15 sec 1 min 
Temperature 50 °C 95 °C 95 °C 60 °C 
 
Thermal cycling took approximately 2 hours.  Data was then analysed using the accompanying 
Applied Biosysetms Sequence Detection System (SDS) software (v2.3). 
2.6   Glutamine flux – Mass Spectrometry 
 
In an attempt to characterise the intracellular concentration and flux of glutamine in 
proliferating CD4+ T lymphocytes we collaborated with the Department of Medical 
Biochemistry at Oslo University Hospital.  Mass spectrometry is a method for determining the 
composition of a sample; including the mass, chemical and electrical properties of the particles 
and molecules that make up the sample62.  In a typical mass spectrometry measurement  the 
sample (be it solid, liquid or gas) is first ionized then forced through an analyser comprising of 
electric and magnetic fields which affects the ionised sample’s speed and direction according to 
its mass and charge.  The ions pass into a detector which identifies and quantifies the analyte 
depending on its trajectory and latency. 
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Mass spectrometry sample preparation  
On the seventh day of the 7 day expansion assay (described earlier under CD4+ T lymphocyte 
activation) the expanding CD4+ T lymphocyte population was transferred to two 50ml Falcon 
Conical Tubes and centrifuged at 1500RPM for 7 minutes.  The supernatant was removed and 
discarded and the cell pellets gently resuspended in 10ml of 36.5 °C PBS to wash the cells of the 
original cell medium.  This step was repeated twice.   The cells were then counted using the 
TC10 Cell Counter (Biorad) and then, depending on total yield, resuspended in a 13C-glutamine 
medium (DM5030; 13C-glutamine 500uM; Glucose 5mM; NaHCO3 3.7g/ml; 0.5% Penicillin-
Streptomycin; 36.5°C) to allow for distribution of 150ul cell medium with approx. 750 000 CD+ 
lymphocytes into 1.5ml Eppendorf tubes. The tubes were kept in a 36.5 °C water bath to 
maintain optimum temperatures.  Two holes were pierced in the Eppendorf tube lids.  The tubes 
were then incubated for 0, 2, 4, 8 and 24 hours at 36.5°C.  After incubation the tubes were 
centrifuged at high speed (15000RPM) for 10 seconds and the medium removed and saved in 
separate Eppendorf tubes.  The cell pellet was washed with 300ul PBS then centrifuged again at 
15000RPM for 10 seconds.  This was repeated two times to remove the labelled glutamine 
medium.  The cell pellets and the saved medium were then lysed with 450ul -80°C 80% MS-
grade Methanol (Merck), left at room temperature for 10 minutes then centrifuged again at high 
speed for 1 minute.   The supernatants of both samples were then transferred into fresh 1.5ml 
Eppendorf tubes and, along with the cell pellets, snap frozen in a -78°C Ethanol/dry ice solution 
and stored in a -80°C freezer for mass spectrometry analysis. 
 
This protocol was also used in an attempt to characterise the flux of glutamine into proliferating 
CD4+ T lymphocytes in the presence of the two Glutaminase inhibitors: compound 968 and 
BPTES.  All parameters were identical.  In addition, 0.75ul BPTES /968 (20mM stocks; 100% 
DMSO) was added to specific Eppendorf tubes directly before incubation to achieve a final 
concentration of 100uM.  Samples were incubated once again for 0, 2, 4, 8 & 24 hours at 36.5°C 
and then processed for mass spectrometry in the procedure described above. 
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2.8  Glutaminase inhibition – protein 
 
The effects of compound 968 and BPTES were also tested on an in vitro Glutaminase enzyme 
assay.   Figure 16 (below) shows the two-step catabolism of glutamine to α-ketoglutarate and 
NADH in the presence of the enzymes Glutaminase (GLS) and glutamate dehydrogenase (GDH).  
Using a micro plate reader the appearance of NADH in the second reaction was quantified as a 
measurement of Glutaminase activity, alone and in the presence of the inhibitors.  The effect of 
phosphate on Glutaminase activity was also measured. 
 
Figure 16.   Two step reaction to form alpha-ketoglutarate and NADH from glutamine through glutamate.  
GLS – Glutaminase; GDH – Glutamate Dehydrogenase. 
 
The first assay was performed as per Table 7 (below).  All components were prepared and 
stored on ice.  5 minutes before assay start they were removed from the ice and allowed to 
warm to room temperature. 
Table 7. Reaction components. 
Reaction mix (2x) 
  
Glutaminase mix (2.5x) 
  NAD (Roche) 
 
4mM 
 
Glutaminase** (100mM, 1mM, 10nM) 
GDH* 
 
6 units 
 
TRIS-acetate 50mM 
  L-glutamine 8mM 
      TRIS-acetate buffer 50mM 
      K2PO4 
 
100mM 
      * Glutamate Dehydrogenase (Sigma) 
** E. coli (Sigma) 
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Five uL of 10% DMSO was added to a 96-well, flat-bottomed, clear microplate followed by 20ul 
of Glutaminase mix.  Finally, 25ul of Reaction mix was added and the microplate placed in a 
Fluorostar OPTIMA microplate reader (BMG Labtech) which had previously been configured 
(96-well plate/Greinar BioOne; 50ul well volume; 340-10 Excitation filter; wavelength 
adjusted).  All tests were performed in triplicates.  Blank (50ul TRIS-acetate) and Negative 
controls (minus Glutaminase mix) were included.  Blank corrected, raw and average data was 
exported to Excel.  In the second assay the 5ul of 10% DMSO was substituted for 5ul from stock 
solutions of BPTES/968 (10% DMSO; 50mM TRIS-Acetate buffer) to achieve final 
concentrations of 0.1, 1, 10 & 100uM.  No dipotassium phosphate was used in the second assay. 
 
3.0     RESULTS 
3.1  Characterisation of Glutaminase isoforms in naive CD4+ T cells  
 
The isoforms of Glutaminase in CD4+ T cells are not well characterized. Therefore, we prepared 
western blots of protein extracts prepared from CD4+ T cells (Figure 16). Naïve mature CD4+ 
lymphocytes were isolated from buffy coats as described under Methods.  Cells were lysed, 
diluted in an SDS sample buffer and total protein (15ug/lane) separated by SDS-PAGE in a 7.5% 
acrylamide gel. Fractionated proteins were transferred to PVDF membranes which were 
incubated with antibodies to the three known Glutaminase isoforms: KGA (250-1000:1), GAC 
(600:1) and LGA (500:1); in addition to a control, α-tubulin (5000:1).  Figure 17 depicts KGA 
(73kDa) and to a lesser extent GAC (55kDa), but not LGA (66kDa), are expressed at detectable 
levels using this method in CD4+ T lymphocytes. 
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Figure 17. Relative Glutaminase isoenzyme levels in resting mature CD4+ lymphocytes.  Lane 1 - α-
tubulin (55kDa); Lane 2 - KGA (arrow; 73kDa); Lane 3 - GAC (arrow; 55kDa); Lane 4 – LGA (not visible).  
 
3.3  Characterisation of Glutaminase isoforms in activated CD4+ T cells 
 
Since expression of the KGA and GAC Glutaminase isoforms was evident in naïve CD4+ T 
lymphocytes, we next investigated if the same set of Glutaminase isoforms were expressed in 
CD4+ T lymphocytes activated through their CD3 and CD28 cell surface markers. 
 
CD4+ T lymphocytes were activated as described under Methods.  Figure 18 depicts that within 
minutes of the addition of the anti-CD3 and anti-CD28 coated beads, CD4+ lymphocytes begin to 
surround individual beads (photos C & D).    A successful stimulation was evident from the 
yellow medium and “budding” of the activated T cells; and the relative homogenous cell 
dispersion & cell morphology, and pink medium of the non-stimulated wells (A & B).  At 72 
hours the activated cells have conglomerated around beads and swelled in size (E & F).   
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Figure 18. Images of naïve and activated CD4+T  lymphocytes in cell culture. A/B: Naive CD4+ 
lymphocytes (4x)/(40x)- the arrow on the left indicates a single CD4+ T lymphocyte; C/D: CD4+ lymphocytes 
stimulated with Dynal beads (dark-arrow) after 2 min incubation(4x)/(40x) – the arrow indicates a single 
Dynal bead; E/F: Stimulated CD4+ lymphocytes after 72 hours incubation time (4x)/(40x). 
 
To confirm that the budding and morphological changes of the CD4+ cells seen in the above 
photos were a result of CD3/CD28 activation a solution containing a radioactive nucleoside, 3H-
thymidine, was added to the cell medium after 48 hours.  The rate of 3H-thymidine 
incorporation into DNA of the CD4+ T cells was then measured after 24 hours using a 
scintillation counter. 
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Figure 19. 3H-thymidine nucleoside incorporation into newly synthesized DNA in stimulated and non-
stimulated CD4+ lymphocytes. Radioactivity measured in counts per minute (cpm). 
 
Figure 19 demonstrates that after addition of the CD3/CD28 activation beads the rate of 3H-
thymidine uptake and incorporation into newly synthesized DNA over the 24 hours increased 
from approximately 600 (+/- 60) cpm to 125,000 (+/-10,000) cpm confirming successful 
activation. 
To determine the relative expression of the three Glutaminase isoenzymes in CD3/CD28 
activated CD4+ T cells we again prepared samples and separated total protein in the manner 
described previously (and in more detail in Methods).  Figure 20 demonstrates that after 
CD3/CD28 activation there appears to be a considerable drop in the relative level of the KGA 
Glutaminase isoform (73kDa) and a concurrent increase in the level of the GAC isoform (55kDa).  
This was accompanied by the appearance of non-specific banding on both the KGA blot (approx. 
48kDa) and GAC blot (approx. 42kDa) that were not present in the non-activated blots.  Once 
again the LGA isoform was not detected.  
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Figure 20. Relative Glutaminase isoenzyme levels in CD3/CD28-activated CD4+ lymphocytes. Lane 1 - α-
tubulin (55kDa); Lane 2 - KGA (arrow; 73kDa); Lane 3 - GAC (arrow; 55kDa); Lane 4 – LGA (not visible). 
 
In an attempt to understand the dynamics of this change in relative isoenzymes expression 
between KGA and GAC we set up a time course assay that could examine the relative protein 
levels in 12 hour intervals for a total of 72 hours after activation.  The procedure used was 
identical to the one described earlier.  This demonstrated (as illustrated in Figure 21) that KGA 
levels drop rapidly in the first 12 hours after CD4+ T lymphocyte activation.  Concurrently, there 
is a slightly delayed increase in the relative concentration of the GAC isoform which reversed 
after 24 hours.  This decrease in GAC concentration was not consistent with the previous blot 
where the presence of an intense band indicated high GAC levels at 72 hours. 
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Figure 21. Relative Glutaminase isoenzyme concentration at rest (0 hours) and at 12 hour intervals after 
CD3/CD28 activation (total 72 hours). Upper box - KGA (73kDa); Middle box – GAC (55kDa); Lower box - α-
tubulin (55kDa). 
 
3.3  qPCR – Gene Expression 
 
Our results showed elevated levels of the GAC Glutaminase isoform and a concurrent decrease 
in the KGA isoform in CD4+ t lymphocytes activated via their CD3 and CD28 surface markers.  
Next we wanted to determine whether this dynamic would be evident at the genetic level. 
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Figure 22. Relative mRNA concentrations of Glutaminase isoenzymes in proliferating CD4+ lymphocytes 
compared to naïve cells. RQ – Relative Quantification. 
 
Total RNA was isolated from the CD4+ T cell samples and used to synthesize complementary 
DNA using reverse transcription. Each cDNA template was then probed three times: once for 
each of the LGA, KGA & GAC Glutaminase isoenzymes and amplified using real-time polymerase 
chain reaction (RT-PCR) (see Methods).  Figure 22 indicates a slight increase in relative 
concentrations of mRNA coding for the GAC protein; a weaker increase for the LGA isoform; and 
no relative change for the KGA form in CD3/CD28-activated CD4+ lymphocytes relative to naïve 
cells.   
3.5  Glutamine removal 
 
According to the literature, cancer cell transformation is associated with what has been 
described as “glutamine addiction”47.  Based on this we wanted to determine how the removal of 
glutamine from the cell medium would affect the growth of activated CD4+ T lymphocytes.   
 
Stimulation of the CD4+ lymphocytes was achieved in a manner described earlier and under 
Methods.  Cells were incubated in a 96-well plate for 48 hours in cell mediums with varying 
concentrations of glutamine (0.01 – 10uM).  Twenty five uL of 3H-thymidine was then added to 
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each well and allowed to incubate for a further 24 hours.  3H-thymidine incorporation was then 
measured using a scintillation counter to determine the rate of growth. 
 
Results showed that reducing the concentration of glutamine in the cell growth medium below 
1mM had a profound impact on CD4+ T cell proliferation, despite the availability of glucose (see 
Figure 23).   Proliferation was shown to be stable in glutamine concentrations higher than 1mM, 
with a subsequent sharp decline between 1 and 0.1mM.    It appeared that at glutamine 
concentrations below 0.1uM cells proliferation was almost completely arrested.  
 
 
Figure 23. CD3/CD28-activated CD4+ T lymphocyte 3H-thymidine incorporation in growth medium with 
limiting glutamine concentrations. Radioactivity measured in counts per minute (cpm). 
 
3.6  Glutaminase inhibition – CD4+ T Lymphocytes 
 
Our results demonstrated that activated CD4+ lymphocytes are dependent on glutamine to 
proliferate.  Next we wanted to determine if blocking glutamine metabolism would have a 
similar effect on activated CD4+ T lymphocytes.  
  RESULTS 
54 
 
CD4+ T lymphocytes were activated via their CD3/CD28 surface markers by magnetic beads 
and incubated in a standard growth medium as described in detail in Methods.  In addition, two 
known Glutaminase inhibitors were added to the medium: compound 938 and BPTES (detailed 
in Introduction).  3H-thymidine was added to each well after 48 hours and rate of incorporation 
was measured after a further 24 hours by a scintillation counter.  Our results, as shown in 
Figure 24, demonstrate that the introduction of the Glutaminase inhibitors had a noticeable 
impact on 3H-thymidine incorporation at concentrations higher than 1uM: >50% reduction at 
10uM and almost complete reduction (Compound 968) at 100uM (p<0.05).  Interestingly, a 
slight increase in proliferation was observed in BPTES-inhibited wells above that of the 
stimulated cells without inhibitors.   
 
 
Figure 24. [3H]-Thymidine incorporation of CD3/CD28-activated CD4+ lymphocytes in the presence of 
Glutaminase inhibitors 968 & BPTES. Radioactivity measured in counts per minute (cpm). 
 
3.7  Glutaminase inhibition - protein 
 
The ability of activated CD4+ T lymphocytes to synthesize new biomass appeared to be 
significantly reduced through the introduction of Glutaminase inhibitors.  We wanted to confirm 
that the two Glutaminase inhibitors were actually inhibiting Glutaminase, and that the results 
seen above were not a result of some other phenomenon.  
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First, activity of Glutaminase derived from Escherichia Coli was quantified by measuring the 
appearance of NADH generated in the second reaction of the catabolism of glutamine to α-
ketoglutarate (see Methods).  In a 96 well clear-bottomed microplate a solution containing 
NAD+, Glutamate Dehydrogenase and glutamine in a TRIS-acetate buffer was mixed with a 
solution of Glutaminase (see Methods for more details).  A phosphate mixture was also included 
to determine its effect on Glutaminase activity.  NADH appearance was measured using a 
microplate reader and the absorbance of UV light at 340nm.  
Figure 25 depicts a dose-response relationship between the concentration of Glutaminase and 
the appearance of NADH in our tests.  Our results also showed that in the presence of phosphate 
the conversion of glutamine to α-ketoglutarate appears to be attenuated. 
 
Figure 25. NADH appearance as a measurement of Glutaminase activity. NADH concentration 
measured by UV absorbance at 340nm.  Grey bars - 50mM K2PO4; Black bars – phosphate free. Glutaminase 
derived from E. coli. 
 
Next, compound 968 and BPTES were added in serial dilutions (0.1 – 100uM) to the reaction 
mixture described above.  Once again NADH appearance through 340nm UV absorption was 
used to determine Glutaminase activity. 
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Figure 26. NADH appearance as a measurement of Glutaminase activity in the presence of inhibitors: 
968 and BPTES. NADH concentration measured by UV absorbance at 340nm.  Black bar – no inhibitor; light 
grey – BPTES; dark grey – 968.  Glutaminase derived from E. coli. 
 
Together these experiments demonstrated that Glutaminase activity is powerfully inhibited by 
both inhibitors in vitro at all concentrations by up to 90% (Figure 26).   
3.4  Glutamine flux – Mass Spectrometry 
 
Based on the results depicted in figures 22-26, we suggest that T cell proliferation induced 
through the TCR/CD3-CD28 complex requires the presence of glutamine.  Therefore, we wanted 
to characterise the intracellular concentration, and flux of extracellular added, glutamine in 
proliferating CD4+ T lymphocytes with and without the use of the two Glutaminase inhibitors. 
Proliferating CD4+ T cells were generated through a 7-day extended version of the CD4+ T cell 
activation protocol explained in detail in Methods.  After 7 days the cells were washed free of the 
growth medium and then incubated for up to 24 hours in a 500uM 13C-glutamine-labelled cell 
medium.  The medium and the cell pellet where then lysed with 80% methanol and then 
analysed using mass spectrometry to determine 13C-glutamine concentrations. Figure 27 clearly 
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depicts a steady reduction (up to 60% after 24 hours) in the amount of labelled-glutamine 
present in the cell medium during the measurement period (0-24 hours).   
 
Figure 27. Glutamine consumption from cell medium containing proliferating CD4+ T lymphocytes.  
Grey bars depict relative medium glutamine concentrations in intervals over 24 hours. 
 
To investigate if the reduction in media glutamine was associated with Glutaminase activity we 
added 968 and BPTES and measured glutamine levels over a time course of 0 to 24 hours. 
 
Figure 28. Glutamine consumption from cell medium containing BPTES and a CD4+ T lymphocyte 
population. Grey bars depict relative medium glutamine concentrations in intervals over 24 hours. 
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Figure 29.  Glutamine consumption from cell medium containing 968 and a CD4+ T lymphocyte 
population. Grey bars depict relative medium glutamine concentrations in intervals over 24 hours. 
 
This demonstrated that glutamine reduction in the media was comparably reduced regardless 
of the presence of inhibitors.  Figures 28 and 29 (above) show similar patterns of glutamine 
reduction from the cell medium.   
To investigate if glutamine was taken up by the T cells we measured relative intracellular 
concentrations of glutamine up to 24 hours in the presence and absence of the glutamine 
inhibitors BPTES and 968 (see figures 30, 31 and 32).   
 
Figure 30. Relative intracellular concentrations of glutamine in proliferating CD4+ lymphocytes in 
the presence of the Glutaminase inhibitor, BPTES. Grey bars depict relative medium glutamine 
concentrations in intervals over 24 hours. 
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Figure 31. Relative intracellular concentrations of glutamine in proliferating CD4+ lymphocytes in 
the presence of the Glutaminase inhibitor, 968. Grey bars depict relative medium glutamine 
concentrations in intervals over 24 hours. 
 
Figure 32. Relative intracellular concentrations of glutamine in proliferating CD4+ minus 
Glutaminase inhibitors. Grey bars depict relative medium glutamine concentrations in intervals over 24 
hours. 
 
Finally, a regression analysis was performed on the absolute values to determine the statistical 
relationship between the three assays. 
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Figure 33. A regression analysis of absolute intracellular glutamine levels in the three MS assays.  
Red – BPTES, Blue – 968, Green – no inhibitor.  Grey area denotes 95% confidence percentile. Time = hours 
from assay start. 
 
Figures 30, 31 and 32 demonstrate that the relative levels of intracellular glutamine in CD4+ T 
lymphocytes increase rapidly over the first 4 hours then gradually decline to baseline in a 
similar manner regardless of the presence of the Glutaminase inhibitors.  The BPTES assay 
showed the biggest increase (12 times baseline at 2 hours), while the 968 and non-inhibitor 
assays showed similar values.  This was reflected in the regression analysis of the absolute 
values: There was no statistical difference in intracellular glutamine concentrations between the 
assay with no inhibitor and that containing compound 968.  There was, however, a significant 
increase in the amount of intracellular glutamine in the BPTES assay between hours 0 and 8.  
After 24 hours incubation this statistical difference vanished. 
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4.0  DISCUSSION 
 
Cancer cells exhibit up-regulated glycolytic activity and rapid turnover of biosynthetic 
precursors compared with somatic cells. This proliferative phenotype is common between 
many different proliferating cells.  This relationship allowed us to hypothesize whether the 
“glutamine addiction” seen in cancer cells was applicable to proliferating human lymphocytes, 
and if, ultimately, we could disrupt glutamine metabolism and attenuate proliferation. 
Glutaminase 
The up-regulation of the GAC Glutaminase isoform in activated CD4+ lymphocytes seen in our 
Western Blot analyses is consistent with similar studies on colorectal tumours63, gliomas64, 
central nervous system tumours65 and breast tumours66.  Also compatible is the inconsistency 
between the increase in Glutaminase protein and expression of the gls gene60;63;64.  Our results 
also hinted at a slight increase in mRNA levels of GAC, but the data was not significant and 
exhibited wide variance as to be unreliable.  However, previous studies have demonstrated 
elevated GAC mRNA levels in colorectal carcinomas63, breast tumours66 and glyomas64, with 
concurrent increases in GAC protein concentration. However, a previous study by Szeliga, et al. 
demonstrated a 20 times increase in the level of LGA mRNA in neoplastic cells with no increase 
in protein concentration67.  This may suggest that there is poor correlation between mRNA and 
protein for GLS, at least for certain isoforms.  
The transcription factor myc up-regulates glutamine transporter synthesis and expression, 
increases mitochondrial glutaminolysis, and sensitizes many proliferating cells to glutamine 
withdrawal35;68;69.    Interestingly, up-regulation of myc also corresponds to increased GAC 
expression in B lymphoma and prostate cancer cells49.  In addition, GAC was the only 
Glutaminase isoform located in the mitochondria of lung, breast and prostate cancer cells60. 
Combined, this suggests that the expression of the three Glutaminase isoforms may not be 
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under direct genetic control, but that myc, and perhaps other, undiscovered pathways, may, 
indirectly, control their expression and activity through post-translational modifications.  The 
presence of sub-bands in our western blots taken from activated T lymphocytes may be 
evidence of this.  It also suggests that the up-regulated GAC isoform may offer neoplastic cells a 
selective advantage under proliferation due to its exclusive location in the mitochondria60. 
The kinetics of the three Glutaminase isoforms, particularly GAC, in the presence of phosphate 
may also hint at another selective advantage for T lymphocytes under proliferation.  
Unfortunately we were unable to test the human Glutaminase isoforms.  However, our kinetic 
data demonstrated that in the presence of 50mM of phosphate the activity of Glutaminase 
derived from E. coli was reduced.  This was consistent with other experiments70.  A comparison 
with the mammalian Glutaminase isoforms illustrates the widely differing phosphate-
dependent characteristics that exist between species, and also between isoforms of the same 
species.  The mammalian GAC isoform, for example, is massively up regulated (40x) in solutions 
containing 50mM phosphate whilst the LGA variant is virtually unresponsive60.  This suggests 
that phosphate is required for optimal catalytic efficiency in the human GAC Glutaminase 
isoform, which our results indicate is the dominant isoform in proliferating T cells.  We were 
unable to find any data regarding mitochondrial phosphate concentrations in proliferating 
lymphocytes.  To what extent an increase in mitochondrial phosphate concentration contributes 
to the activation/up-regulation of GAC Glutaminase seen in proliferating T cells remains to be 
seen. 
 
Glutamine dependence 
A dependence of activated T cells on sufficient extracellular glutamine was witnessed in our 3H-
thymidine incorporation assays.  Initially, the cells that were completely deprived of glutamine 
exhibited the same proliferative rate as those with plentiful glutamine.  This led us to speculate 
at whether the glutamine concentration or other crucial factors in the fetal bovine serum (FBS) 
used in the cell medium was negating any effects of the glutamine removal.  Once we had 
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dialyzed the FBS and removed all small molecules below 3500 kDa, including glutamine, we 
immediately got results.  We found that at glutamine concentrations lower than 0.5mM the 
proliferative ability of CD4+ lymphocytes was reduced by approx. 50%; and at 0.1mM, almost 
100%.  This dependency was backed up by our spectral analyses of cell media containing 
proliferating T lymphocytes.  Over a 24 hour period the extracellular glutamine concentration 
was reduced by over 60%.  This rapid glutamine consumption can be seen in many cancer cells, 
with certain tumours consuming so much glutamine they sink plasma glutamine levels67;69.  
Together this suggests that proliferating CD4+ T lymphocytes, as with many other highly 
proliferative cells, are absolutely dependent on adequate extracellular glutamine.  Taken one 
step further it may be suggested that the ability of the immune system as a whole is dependent 
on glutamine.  If this is the case, it may have significant implications from a clinical perspective 
when we consider how best to treat diseases that are known to deplete plasma glutamine levels 
including chronic inflammatory diseases, sepsis, severe burns and malnutrition71. 
 
We have shown that the expression of a highly catalytic glutamine isoform is up-regulated in 
proliferating CD4+ T cells.  In addition, elevated glutamine activity features in many different 
tumour types57;59;67.  When we consider glutamine’s role as a precursor in the metabolic and 
biosynthetic requirements of these cells, it is perhaps of little surprise that intracellular 
glutamine concentrations are low to non-existent72-74.  This suggests that glutamine is 
immediately catabolised once it enters the proliferating cell.  However, our spectral analyses 
examining the intracellular glutamine concentration of proliferating CD4+ T cells did not reflect 
this.  First, the small concentration of intracellular glutamine witnessed at 0 hours may be a 
result of the small delay in freezing/lysing the samples, therefore giving the cells a small 
window of opportunity to take up glutamine from the media.  Despite this, a large increase in 
intracellular glutamine concentration peaked at four hours.  An explanation for this could, in 
part, be explained by the 30-45 minute washing and distribution process performed before the 
cells are suspended in the labelled-glutamine medium.  The washing medium is free of 
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glutamine (and other amino acids).  Glutamine depletion is known to down-regulate glutamine 
transporters75 – this may have had the effect of dampening the glutaminolytic machinery inside 
the cell.  Hence, after glutamine addition and when the transporters up-regulated again, 
glutamine catabolism may have been delayed, thus the temporary increase in glutamine 
concentration.  However, the same washing procedure had no effect on the consumption of 
glutamine from the cell medium seen in the other assays.  It also seems unlikely given the slow 
nature (~12hrs) of the depletory effect75.  Another consideration is the lack of IL-2 from our 
washing medium.  IL-2 depletion has been shown to have an almost instant effect on nutrient 
uptake and metabolism in proliferating T lymphocytes76, but once again this effect was not 
witnessed in the glutamine uptake experiments with the same procedures.  If IL-2 depletion 
affected only the catabolism of glutamine and not the transporters (or there was a delay in its 
effect on the transporters) then this could explain the temporary peak in intracellular 
glutamine.  Moreover, we saw a steady reduction of intracellular glutamine concentration after 
four hours incubation.  Taken together with the steady uptake of glutamine from the cell 
medium, this suggests that there was an increase in glutamine catabolism after four hours.  It is 
clear that our protocol would benefit from a more careful analysis of the signalling effects of IL-
2 and how glutamine depletion affects the cells prior to assay start. 
 
Glutaminase inhibitors 
Recent research has highlighted Glutaminase as an exciting therapeutic target in tumours.  
Specifically, two allosteric Glutaminase inhibitors, compound 968 and BPTES have recently 
been used to slow the growth of glioma cells77 and human breast tumours57.   
 
Glutamine intracellular concentration and flux 
We exposed proliferating CD4+ T cells to both inhibitors and used Mass Spectrometry to analyse 
the glutamine flux from the cell medium, in addition to the intracellular glutamine 
concentration, over a 24 hour period.  Our findings suggest that glutamine inhibition has little 
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effect on glutamine uptake in proliferating CD4+ T lymphocytes with almost identical clearance 
rates between the non-inhibited and inhibited cells.  The pattern of glutamine appearance in the 
cells (increasing over the initial 2-4 hours and then sinking to baseline) between the three 
assays was very similar.  Inhibitor/enzyme association is not instantaneous: the inhibitor must 
infiltrate the cell first and then bind to the enzyme.  Our inhibitors were added to the cells at 0 
hours and had no pre-incubation period. The observed delay in the increase of glutamine inside 
the cell may be a result of this.  It is reasonable to suggest that pre-incubating the cells with the 
inhibitors could result in a much more rapid increase in intracellular glutamine.  Interestingly, 
the intracellular glutamine concentration of the cells exposed to BPTES between 0-4 hours was 
significantly higher (2x) than the control cells and those exposed to 968.  This suggests that the 
inhibitory effect of BPTES was greater than that of 968 - which appeared to have little effect.  
Why this significance gradually disappears over the 24 hours, however, is unclear.  Indeed, the 
steady decline in glutamine concentration from both inhibitor assays is puzzling.  Given the 
steady uptake of glutamine from the cells it may simply be of kinetic nature – the increasing 
glutamine concentration out-competes 968/BPTES for the binding seat on Glutaminase.  
Another interesting proposition is that of an alternate metabolic pathway for glutamine. 
 
Enzyme inhibition 
We exposed recombinant Glutaminase derived from E. Coli to both inhibitors and measured 
Glutaminase activity by the appearance of NADH.  Due to the issues with our protocol detailed 
earlier, we were unable to obtain any convincing data.   Our inability to obtain a dose-response 
relationship may, in part, be due to our references for inhibitor concentrations obtained from 
the literature (IC50 0.14-19uM78,57). Given the structural differences between mammalian 
Glutaminase and Glutaminase from E. Coli a more thorough investigation into ideal inhibitor 
concentrations would be prudent.   Regardless, we did see reduced catalytic activity of the E. 
Coli Glutaminase exposed to both inhibitors at all concentrations used (0.1 – 100uM). This and 
other kinetic analyses of recombinant human Glutaminase exposed to BPTES58;78;79 or 96857;60 
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suggest that the reduced proliferation observed in tumour cells in the presence of these 
inhibitors is a result of Glutaminase inhibition.   
 
CD4+ T lymphocyte inhibition 
With this in mind we exposed CD3/CD28-activated CD4+ T lymphocytes to varying 
concentrations (0.1uM to 100uM) of both 968 and BPTES.  At concentrations higher than 10uM, 
both inhibitors had a detrimental effect on cell proliferation.  This is most likely due to 
conformational changes to mitochondrial Glutaminase and subsequent reduction in 
glutaminolysis.  This reinforces the notion of “glutamine addiction” as a phenomenon common 
to the proliferative phenotype and to our knowledge is the first time a Glutaminase inhibitor has 
been successfully used to blunt lymphocyte proliferation. 
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5.0 CONCLUSION 
 
Over fifty years ago Otto Warburg observed that cancer cells, unlike somatic cells, fermented 
glucose in the presence of available oxygen.  Recently, this seminal discovery has led to the 
identification of a particular phenotype common to many proliferating cells, including 
mammalian lymphocytes.   A key factor in this phenotype is the reliance on glutamine 
catabolism to provide anaplerotic carbon to the TCA cycle, and the generation of the reducing 
agent, NADPH.   
 
This report has identified a specific Glutaminase enzyme, GAC, as up-regulated in proliferating 
CD4+ T lymphocytes.   We also demonstrated the ability of two Glutaminase inhibitors, 
compound “968” and BPTES, to dampen this proliferation.   
 
Unwanted lymphocyte proliferation is a hallmark of autoimmune diseases: a failure of an 
organism to recognize its own tissue and the subsequent immune response mounted against 
this tissue.  Autoimmune diseases including Coeliac disease; Diabetes Mellitus (Type 1); Graves’, 
Addison’s & Sjøgren’s disease; and Rheumatoid Arthritis (RA) are the second highest cause of 
chronic illness, and the top cause of morbidity in women, in the United States80.  RA is 
particularly debilitating and affects 0.5-1.0% (700 million) of the world’s population81.  
Treatments for these diseases are often very non-specific, broad inhibitors of cell proliferation 
which are associated with severe side-effects that greatly diminish recipients’ quality of life. The 
identification of Glutaminase inhibitors that dampen unwanted lymphocyte proliferation 
represents a first step in the development of target-specific drugs that could potentially improve 
the quality of life for sufferers of autoimmune diseases throughout the world. 
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FUTURE PERSPECTIVES 
 
The use of siRNA to target both gls and gls2 genes, in addition to myc, would likely provide 
greater insight into how the genetic machinery regulates the expression of the Glutaminase 
isoforms in naïve and proliferating CD4+ lymphocytes.  Similarly, analyses of the changes in the 
myc protein levels would also be of interest. 
Sub-cellular localisation of the specific Glutaminase enzymes would confirm whether GAC’s 
exclusivity found in certain cancer cells was applicable to T lymphocytes.  It would also be 
interesting to know if intracellular phosphate concentrations change upon 
activation/proliferation, especially in the mitochondria. 
Finally, using mass spectrometry to determine the fraction of glutamine-derived carbon that 
was converted to CO2, lactate, alanine or citrate would provide a greater appreciation of 
glutamine’s role in both naïve and proliferating CD4+ T lymphocytes. 
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Appendix A – Additional Procedures 
 
Slide-A-Lyser Dialysis Kit – removal of glutamine from cell medium 
Modified directly from manufacturer’s website. 
A. Hydrate Membrane 
1. Remove the cassette from its protective pouch. To prevent contamination, handle the cassette by the plastic frame 
only. Do not touch the membrane with ungloved hands. The 12-30mL Slide-A-Lyzer Cassette may be placed on end on 
a flat surface. 
 
2. Hold the float chamber at the top of the unit and immerse cassette in dialysis buffer (PBS) for 2 minutes to hydrate 
membrane. 
 
Note: Hydration increases membrane flexibility and allows it to adjust more readily to the positive pressure created 
as the sample is added and to the vacuum created when air is removed. 
 
3. Remove cassette from buffer and gently tap the cassette edge on a paper towel to remove excess liquid. Do not blot 
the membrane. 
 
B. Add Sample 
 
1. Fill the syringe with the sample, leaving a small amount of air in the syringe. For large sample volumes, fill the 
syringe without the needle in place. 
 
2. Orient the needle bevel sideways and penetrate the gasket through one of the syringe ports at a corner of the 
cassette. Slowly extend the needle into the cavity to a minimal extent and inject approximately half of the sample. For 
samples with high protein concentrations (e.g., 10mg/mL), fill the cassette slowly to avoid foaming. 
 
3. Withdraw some air from the cassette by pulling up on the syringe piston and then inject remaining sample. 
 
4. With the syringe needle inserted in the cassette cavity, withdraw remaining air from the cavity to compress the 
membrane windows so the sample contacts the greatest surface area.  Use caution to prevent the needle from 
contacting the membrane. Minimal air left inside the cassette will not significantly affect dialysis efficiency. 
 
5. Remove the syringe needle from the cassette while retaining air in the syringe. The gasket will reseal and the 
membrane cavity will contain minimal or no air. Mark the cassette corner with a permanent marker or record the 
number of the injected port. 
 
C. Dialyze Sample 
 
1. Float cassette in the dialysis solution of choice and stir gently to avoid creating a vortex that might pull the cassette 
down in contact with the stir bar. 
 
Dialysis times for removal of glutamine: 
  
 1. Dialyse for 2 hours at room temperature. 
 2. Change dialysis buffer and dialyze for another 2 hours. 
 3. Change the dialysis buffer and dialyze overnight at 4°C. 
 
D. Remove Sample 
 
1. Fill syringe with approximately 15mL of air and penetrate gasket with the needle through a top, unused syringe 
guide port. 
  
2. Slowly discharge air into cassette cavity to separate membranes, which prevents needle penetration of the 
membrane. 
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3. With the needle in place, turn the unit so that needle is on the bottom. Allow sample to collect near the port and 
withdraw sample into the syringe. 
 
Pierce BCA Protein Kit – protein concentration 
Modified directly from manufacturer’s website. 
Preparation of Standards and Working Reagent (required for both assay procedures) 
A. Preparation of Diluted Albumin (BSA) Standards 
Use Table 1 as a guide to prepare a set of protein standards. Dilute the contents of one Albumin Standard (BSA) 
ampule into several clean vials, preferably using the same diluent as the sample(s). Each 1mL ampule of 2mg/mL 
Albumin Standard is sufficient to prepare a set of diluted standards for either working range suggested in Table 1. 
There will be sufficient volume  
for three replications of each diluted standard. 
 
Table 1. Preparation of Dilution Albumin (BSA) Standards 
Vial Volume of Dileunt 
(uL) 
Volume and Source of BCA 
(uL) 
Final BSA Concentration 
(ug/mL) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 Blank 
 
B. Preparation of the BCA Working Reagent (WR) 
 
1. Use the following formula to determine the total volume of WR required: 
 
(# standards + # unknowns) × (# replicates) × (volume of WR per sample) = total volume WR required 
 
Note: 2.0mL of the WR is required for each sample in the test-tube procedure, while only 200 µl of WR reagent is 
required for each sample in the microplate procedure. 
 
2. Prepare WR by mixing 50 parts of BCA Reagent A with 1 part of BCA Reagent B (50:1, Reagent A:B). For the above 
example, combine 50mL of Reagent A with 1mL of Reagent B. 
 
Note: When Reagent B is first added to Reagent A, turbidity is observed that quickly disappears upon mixing to yield 
a clear, green WR. Prepare sufficient volume of WR based on the number of samples to be assayed. The WR is stable 
for several days when stored in a closed container at room temperature (RT). 
 
Microplate Procedure (Sample to WR ratio = 1:8) 
 
1. Pipette 25µL of each standard or unknown sample replicate into a microplate well (working range = 20-
2000µg/mL) 
 
Note: If sample size is limited, 10µL of each unknown sample and standard can be used (sample to WR ratio = 1:20). 
However, the working range of the assay in this case will be limited to 125-2000µg/mL. 
 
2. Add 200µL of the WR to each well and mix plate thoroughly on a plate shaker for 30 seconds. 
 
3. Cover plate and incubate at 37°C for 30 minutes. 
 
4. Cool plate to RT. Measure the absorbance at or near 562nm on a plate reader.
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Appendix B – List of solutions and reagents 
 
NAME SUPPLIER CATALOG # 
CD4+ isolation 
  Phosphate Buffered Solution (PBS) Sigma D8537 
RPMI1640 Sigma-Aldrich R0883 
Dynabeads CD4+ Isolation Kit Invitrogen 11331D 
 
  Lysation 
  NP40 Lysis buffer Novex FNN0021 
PMSF Protease Inhibitor Sigma P7626 
Protease Inhibitor Cocktail Sigma P8340 
Ethanol Merck 108543 
Lgepal CA-360 Sigma I3021 
 
  Pierce BCA Protein Assay 
  Pierce BCA Protein Assay Kit Thermo Scientific 23223 
 
  Western Blotting 
  α-GAC antibody (Rb pAb) Protein Tech 19958-1-AP 
α-KGA antibody (Ms mAb) Abcam ab60709 
α-LGA antibody (Rb pAB) Abcam ab91073 
α-alpha-tubulin antibody (Rb mAb) Sigma 081M4861 
SDS (sodium dodecyl sulphate) Biorad 161-0302 
Glycine VWR 101196X 
NaCl Merck 1.06404.1000 
Methanol Merck MX0490 
Tween 20 Sigma 101102360 
 
TRIS Calbiochem 
 
648310 
Precision Plus Dual Colour Standard Biorad 161-0374 
Criterion 12+2well 7.5% HCL-TRIS Gel Biorad 345-0005 
Criterion 18 well 7.5% HCL-TRIS Gel Biorad 345-0006 
PVDF Transfer Membrane  Millipore IPVH00010 
Super Signal West Pico Chemilumiescent Kit Thermo Scientific 34080 
Restore Western Blot Stripping buffer Thermo Scientific 46430 
Criterion Filter Paper 
 Biorad 1704085 
CD4 stimulation 
  Dynabeads CD3/CD28 Expansion Beads Invitrogen 11131D 
Dynabeads Mouse T-Activator CD3/CD28 Beads Invtirogen 11456D 
Interleukin 2 (IL-2) PeproTech 200-02 
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[3H]-Thymidine CD4+ Stimulation Test 
[3H]-Thymidine  Nerliens 27X005MC 
   qPCR 
  
RNeasy Plus Mini Kit Qiagen 74134 
QuantiTect Reverse Transcription Kit Qiagen 205311 
β-mercaptoethanol Sigma 129112 
Rnase-free water Qiagen 129112 
TaqMan Gene Expression Kit Applied Biosystems 4369016 
TaqMan GAC Probe Applied Biosystems HS01022166_m1 
TaqMan KGA Probe Applied Biosystems HS01014013_m1 
TaqMan LGA Probe Applied Biosystems HS00998733_m1 
TaqMan B2M Probe Applied Biosystems HS99999907_m1 
   Mass Spectrometry 
  13C-L-glutamine Aldrich 607983 
MS-grade Methanol Merck 600-001-00 
   Glutamine removal 
  Pierce Slide-A-Lyzer Dialysis Cassette 3.5K MWCO 30ml Thermo Scientific 66130 
   Glutaminase inhibition 
  Compound 968 SPECS 36107028 
BPTES Drug Discovery Lab AS 
 
Glutaminase E.coli Sigma G8880 
L-GDH Sigma 1001153002 
NAD Roche 10127965001 
DMSO Sigma 276855  
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Appendix C – Protein/RNA Concentrations 
 
Nanodrop 2000c Spectrophotometer 
Table x. Total protein concentrations in naïve and CD3/CD28-activated CD4+ T lymphocytes. 
Donor Sample mg/ml A280 
absorbance 
260/280 ab. ratio 
1 
Naive 19.31 19.31 0.56 
Activated 22.211 22.211 0.7 
2 
Naive 20.214 20.214 0.58 
Activated 22.599 22.599 0.7 
3 
Naive 16.502 16.502 0.73 
Activated 15.772 15.772 0.57 
4 
Naive 1.572 1.572 -0.51 
Activated 3.533 3.533 1.38 
5 
Naive 1.971 1.971 -0.13 
Activated 1.532 1.532 -0.63 
6 
Naive 2.681 2.681 0.92 
Activated 2.527 2.527 1.08 
 
Table x. Total RNA concentrations in naïve and CD3/CD28-activated CD4+ T lymphocytes. 
Donor Sample ng/ul A260 
absorbance 
A280 
absorbance 
260/280 
absorbance ratio 
1 
Naive 58.4 0.697 2.1 1.9 
Activated 266.8 3.206 2.08 2.12 
2 
Naive 256.5 3.084 2.08 2.12 
Activated 46.1 0.547 2.11 1.79 
3 
Naive 45.3 0.532 2.13 1.87 
Activated 237.4 2.87 2.07 2.13 
4 
Naive 271.8 3.287 2.07 2.11 
Activated 115.5 1.406 2.05 1.93 
 
Pierce BCA Protein Assay 
Table x. Total protein concentrations in naïve and CD3/CD28-activated CD4+ T lymphocytes. 
Donor Sample 560nm absorbance ug/ml 
7 
Naive 0.300 774 
Activated 0.436 1225 
8 
Naive 0.233 550 
Activated 0.407 1130 
9 
Naive 0.405 1124 
Activated 0.268 667 
 
